CDC_Test_ID,Test_Case_Name,DOB,Gender,Observation_Code_1,Observation_Text_1,Observation_Date_1,Observation_Code_2,Observation_Text_2,Observation_Date_2,Observation_Code_3,Observation_Text_3,Observation_Date_3,Series_Status,Date_Administered_1,Vaccine_Name_1,CVX_1,MVX_1,Evaluation_Status_1,Series_Type_1,Evaluation_Reason_1,Date_Administered_2,Vaccine_Name_2,CVX_2,MVX_2,Evaluation_Status_2,Series_Type_2,Evaluation_Reason_2,Date_Administered_3,Vaccine_Name_3,CVX_3,MVX_3,Evaluation_Status_3,Series_Type_3,Evaluation_Reason_3,Date_Administered_4,Vaccine_Name_4,CVX_4,MVX_4,Evaluation_Status_4,Series_Type_4,Evaluation_Reason_4,Date_Administered_5,Vaccine_Name_5,CVX_5,MVX_5,Evaluation_Status_5,Series_Type_5,Evaluation_Reason_5,Date_Administered_6,Vaccine_Name_6,CVX_6,MVX_6,Evaluation_Status_6,Series_Type_6,Evaluation_Reason_6,Date_Administered_7,Vaccine_Name_7,CVX_7,MVX_7,Evaluation_Status_7,Series_Type_7,Evaluation_Reason_7,Forecast_#,Earliest_Date,Recommended_Date,Past_Due_Date,Administrative_Guidance,Vaccine_Group,Assessment_Date,Evaluation_Test_Type,Date_added,Date_updated,Forecast_Test_Type,Reason_For_Change,Changed_In_Version
2015-UC-0012,Varicella: Zoster dose administered at 50 years - 1 day,05/29/1965,F,55,Health care personnel,,,,,,,,Not Complete,05/28/2015,Zostavax,121,,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,06/25/2015,06/25/2015,07/22/2015,,Var,05/28/2015,Vaccine: Off Label,09/22/2017,12/09/2019,Recommended based on interval,updated test case title and description.,4.1
2016-UC-0002,Anaphylaxis to previous dose,10/10/2010,F,80,Adverse reaction to vaccine component,,,,,,,,Contraindicated,12/10/2010,DTaP Unspecified,107,,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,DTaP,12/10/2010,All Valid: Forecast Test,01/01/2013,03/21/2019,Not recommended: contraindication,Added description,4
2016-UC-0003,Encephalopathy within 7 days of Pediarix.,02/02/2011,F,79,Encephalopathy not attributable to another identifiable cause within 7 days of administration of a previous dose of Tdap DTP or DTaP vaccine,,,,,,,,Not Complete,04/02/2011,PEDIARIX,110,SKB,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,04/30/2011,06/02/2011,07/29/2011,,DTaP,04/02/2011,All Valid: Forecast Test,01/01/2013,03/21/2019,Recommended based on age,Added description,4
2016-UC-0004,Anaphylaxis to previous dose of Pediarix,10/10/2010,F,80,Adverse reaction to vaccine component,,,,,,,,Contraindicated,12/15/2010,PEDIARIX,110,SKB,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,DTaP,12/15/2010,All Valid: Forecast Test,01/01/2013,03/21/2019,Not recommended: contraindication,Added description,4
2016-UC-0005,Anaphylaxis to previous dose of Pentacel,06/06/2010,F,80,Adverse reaction to vaccine component,,,,,,,,Contraindicated,08/02/2010,PENTACEL,120,PMC,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,DTaP,08/02/2010,All Valid: Forecast Test,01/01/2013,03/21/2019,Not recommended: contraindication,Added description,4
2016-UC-0006,Anaphylaxis following previous dose of Influenza,07/04/2013,F,85,Severe allergic reaction after previous dose of Influenza,,,,,,,,Contraindicated,10/08/2014,Influenza Unspecified,88,,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Flu,10/08/2014,All Valid: Forecast Test,01/01/2013,03/21/2019,Not recommended: contraindication,Added description,4
2016-UC-0007,Anaphylaxis to previous dose of Hep A. No forecast.,03/03/2003,F,96,Severe allergic reaction after previous dose of Hepatitis A,,,,,,,,Contraindicated,03/04/2009,Hep A Unspecified,85,,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,HepA,03/04/2009,All Valid: Forecast Test,01/01/2013,03/21/2019,Not recommended: contraindication,Added description,4
2016-UC-0008,Anaphylaxis to previous dose of Hep B. No further forecast.,09/09/2006,F,97,Severe allergic reaction after previous dose of Hepatitis B,,,,,,,,Contraindicated,11/11/2006,RECOMBIVAX-PEDS,8,MSD,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,HepB,11/11/2006,All Valid: Forecast Test,01/01/2013,03/21/2019,Not recommended: contraindication,Added description,4
2016-UC-0009,Anaphylaxis to previous dose of Pentacel (Hib),06/06/2010,F,80,Adverse reaction to vaccine component,,,,,,,,Contraindicated,08/02/2010,PENTACEL,120,PMC,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Hib,08/02/2010,All Valid: Forecast Test,01/01/2013,03/21/2019,Not recommended: contraindication,Added description,4
2016-UC-0010,Anaphylaxis to previous dose of HPV Vaccine,05/19/2000,F,90,Severe allergic reaction after previous dose of HPV,,,,,,,,Contraindicated,06/19/2011,HPV Unspecified,137,,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,HPV,06/19/2011,All Valid: Forecast Test,01/01/2013,03/21/2019,Not recommended: contraindication,Added description,4
2016-UC-0011,Anaphylaxis to previous dose of MCV,02/26/2000,F,95,Severe allergic reaction after previous dose of Meningococcal,,,,,,,,Contraindicated,03/15/2011,Meningococcal MCV4 Unspecified,147,,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Meningococcal,03/15/2011,All Valid: Forecast Test,01/01/2013,03/21/2019,Not recommended: contraindication,Added description,4
2016-UC-0012,Anaphylactic reaction to dose 1 of MMR. No forecast for additional dose.,08/13/2010,F,91,Severe allergic reaction after previous dose of Measles,,,,,,,,Contraindicated,09/02/2011,M-M-R II,3,MSD,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,MMR,09/02/2011,All Valid: Forecast Test,01/01/2013,03/22/2019,Not recommended: contraindication,Added description,4
2016-UC-0013,Diagnosis of severe immunodeficiency. No forecast for MMR.,09/10/2011,F,154,HIV/AIDS - severely immunocompromised,,,,,,,,Contraindicated,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,MMR,09/10/2011,No Doses Administered,01/01/2013,03/22/2019,Not recommended: contraindication,Updated Observation code to 154 and added description.,4
2016-UC-0014,Anaphylaxis to previous dose of PCV7. No forecast.,07/11/2007,F,94,Severe allergic reaction after previous dose of Pneumococcal,,,,,,,,Contraindicated,09/11/2007,PREVNAR 7,100,WAL,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Pneumococcal,09/11/2007,All Valid: Forecast Test,01/01/2013,03/22/2019,Not recommended: contraindication,Added description,4
2016-UC-0015,Anaphylaxis to previous dose. No forecast.,07/24/2011,F,81,Severe allergic reaction after previous dose of Polio,,108,Severe allergic reaction to streptomycin,,,,,Contraindicated,09/24/2011,IPOL,10,PMC,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,POL,09/24/2011,All Valid: Forecast Test,01/01/2013,03/22/2019,Not recommended: contraindication,Added description,4
2016-UC-0016,Severe combined immunodeficiency (SCID)=no rotavirus vaccine,02/01/2012,F,13,Severe Combined Immunodeficiency [SCID],,,,,,,,Contraindicated,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Rota,03/14/2012,No Doses Administered,01/01/2013,07/29/2019,Not recommended: contraindication,Updated assessment date,4
2016-UC-0017,Anaphylaxis following previous dose,02/01/2012,F,83,Severe allergic reaction after previous dose of Rotavirus,,,,,,,,Contraindicated,04/01/2012,ROTARIX,119,SKB,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Rota,04/01/2012,All Valid: Forecast Test,01/01/2013,03/22/2019,Not recommended: contraindication,Added description,4
2016-UC-0018,Anaphylaxis following previous dose,02/01/2012,F,83,Severe allergic reaction after previous dose of Rotavirus,,,,,,,,Contraindicated,04/01/2012,ROTATEQ,116,MSD,Valid,standard,,05/01/2012,ROTARIX,119,SKB,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Rota,05/01/2012,All Valid: Forecast Test,01/01/2013,03/22/2019,Not recommended: contraindication,Added description,4
2016-UC-0019,History of VZ,05/01/2004,F,24,Healthcare provider verified history of or diagnosis of Varicella,04/01/2005,,,,,,,Immune,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Var,04/01/2005,No Doses Administered,01/01/2013,03/22/2019,Not recommended: immune,Added description,4
2016-UC-0020,Titer of immunity to VZ=series complete or exempt,06/01/2005,F,24,Healthcare provider verified history of or diagnosis of Varicella,,,,,,,,Immune,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Var,06/01/2006,No Doses Administered,01/01/2013,07/29/2019,Not recommended: immune,Updated assessment date,4
2016-UC-0021,Anaphylactic reaction to dose 1 of VZ,12/12/2010,F,89,Severe allergic reaction after previous dose of Varicella,,,,,,,,Contraindicated,03/15/2012,VARIVAX,21,MSD,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Var,03/15/2012,All Valid: Forecast Test,01/01/2013,03/22/2019,Not recommended: contraindication,Added description,4
2016-UC-0022,Diagnosis of severe immunodeficiency. No second dose.,12/12/2009,F,154,HIV/AIDS - severely immunocompromised,,,,,,,,Contraindicated,12/20/2010,VARIVAX,21,MSD,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Var,12/20/2010,All Valid: Forecast Test,01/01/2013,03/22/2019,Not recommended: contraindication,Updated observation code to 154 and added description,4
2016-UC-0023,Diagnosis of severe immunodeficiency before administration of any VZ. No VZ to be given.,11/18/2010,F,154,HIV/AIDS - severely immunocompromised,,,,,,,,Contraindicated,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Var,11/18/2011,No Doses Administered,01/01/2013,07/29/2019,Not recommended: contraindication,Updated assessment date,4
2016-UC-0024,Varicella: Patient has laboratory evidence of immunity for Varicella,06/16/1990,F,23,Laboratory Evidence of Immunity or confirmation of Varicella disease,,,,,,,,Immune,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Var,06/16/1991,No Doses Administered,06/23/2015,07/29/2019,Not recommended: immune,Updated assessment date,4
2016-UC-0025,Varicella: Patient has a Varicella verifiable diagnosis by a healthcare provider.,06/16/1983,F,24,Healthcare provider verified history of or diagnosis of Varicella,,,,,,,,Immune,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Var,06/16/2004,No Doses Administered,06/23/2015,07/29/2019,Not recommended: immune,Updated assessment date,4
2016-UC-0026,Varicella: Patient has a Herpes Zoster verifiable diagnosis by a healthcare provider.,06/19/1972,F,24,Healthcare provider verified history of or diagnosis of Varicella,,,,,,,,Immune,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Var,06/19/2015,No Doses Administered,06/23/2015,07/29/2019,Not recommended: immune,Updated assessment date,4
2016-UC-0027,Varicella: Patient is a healthcare worker with a one-dose history of Varicella vaccine.,03/28/1968,F,55,Health care personnel,,,,,,,,Not Complete,05/28/2015,VARIVAX,21,MSD,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,06/25/2015,06/25/2015,07/22/2015,,Var,05/28/2015,All Valid: Forecast Test,06/23/2015,03/22/2019,Recommended based on interval,Added description and Updated past due date,4
2016-UC-0028,Varicella: Patient is a healthcare worker with evidence of immunity for Varicella.,05/20/1968,M,55,Health care personnel,,,,,,,,Complete,07/03/2012,VARIVAX,21,MSD,Valid,standard,,07/31/2012,Varivax,21,,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Var,07/31/2012,All Valid: Forecast Test,06/23/2015,07/29/2019,Recommended based on interval,Updated assessment date,4
2016-UC-0029,Varicella: Patient is pregnant and has not been found to have evidence of immunity for Varicella.,06/19/1977,F,7,Pregnant,,,,,,,,Contraindicated,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Var,06/19/2015,No Doses Administered,06/23/2015,07/29/2019,Not recommended: contraindication,Updated assessment date,4
2016-UC-0031,Zoster Live Vaccine: Anaphylactic reaction to Zoster vaccine components (Gelatin or neomycin),06/16/1955,F,107,Severe allergic reaction to neomycin,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,06/16/2005,06/16/2005,,,Zoster,06/16/2015,No Doses Administered,06/23/2015,03/22/2019,Recommended based on Condition,Updated to reflect that RZV can be used instead of ZVL. The use of the new product removes the test cases from being Contraindicated. Added description,4
2016-UC-0032,MMR: Patient is a healthcare worker born before 1957 has received one dose of the MMR vaccine.,08/12/1955,F,55,Health care personnel,,,,,,,,Not Complete,04/30/2015,M-M-R II,3,MSD,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,05/28/2015,05/28/2015,05/27/2021,,MMR,04/30/2015,All Valid: Forecast Test,06/23/2015,12/05/2019,Recommended based on interval,V4.1 added past due date v 4.0 Updated to reflect that if a patient is a healthcare worker and has received one dose of the MMR vaccine that a second dose should be administered 4 weeks later. Added description.,4.1
2016-UC-0033,Patient is 31 years of age vaccine naive and seeking protection from Hep A,04/01/1985,M,1,Patient seeks protection,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,04/01/1986,04/01/1986,04/28/1987,,HepA,04/23/2016,No Doses Administered,08/01/2016,07/29/2019,Recommended based on Condition,Updated to display accurate forecasting dates assessment date and added description.,4
2016-UC-0034,Patient is an adult seeking protection from Hepatitis A and has received the first dose of the risk 2 dose series.,05/27/1978,M,1,Patient seeks protection,,,,,,,,Not Complete,07/01/2016,Hep A adult,52,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,01/01/2017,01/01/2017,,,HepA,07/01/2016,All Valid: Forecast Test,08/01/2016,03/23/2019,Recommended based on Condition,Added description,4
2016-UC-0035,Patient is an adult seeking protection from Hepatitis A and has received the second dose of the Hep A risk 2- dose series.,03/17/1991,F,1,Patient seeks protection,,,,,,,,Complete,05/01/2016,Hep A adult,52,MSD,Valid,risk,,11/01/2016,Hep A adult,52,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,HepA,11/01/2016,All Valid: Forecast Test,08/01/2016,03/23/2019,Recommended based on Condition,Added description,4
2016-UC-0036,Patient is 55 years of age has chronic liver disease and has not received Hepatitis A vaccine.,04/12/1961,F,15,Chronic liver disease,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,04/12/1962,04/12/1962,05/09/1963,,HepA,08/01/2016,No Doses Administered,08/01/2016,07/29/2019,Recommended based on Condition,Updated Past Due date assessment date and added description,4
2016-UC-0037,Patient has Chronic liver disease and has received the first dose of the Hep A risk Twinrix 3 dose series .,04/12/1961,F,15,Chronic liver disease,,,,,,,,Not Complete,08/01/2016,HepA-HepB,104,SKB,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,08/29/2016,08/29/2016,,,HepA,08/01/2016,All Valid: Forecast Test,08/01/2016,03/23/2019,Recommended based on Condition,Added description,4
2016-UC-0038,Patient has Chronic liver disease and has received the second dose of the Hep A risk Twinrix 3 dose series .,02/15/1967,M,15,Chronic liver disease,,,,,,,,Not Complete,04/01/2016,HepA-HepB,104,SKB,Valid,risk,,04/29/2016,HepA-HepB,104,SKB,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,10/01/2016,10/01/2016,,,HepA,04/29/2016,All Valid: Forecast Test,08/01/2016,05/22/2019,Recommended based on Condition,Updated to reflect the recommended interval of 5 months for dose #3. and added description,4
2016-UC-0039,Patient has Chronic liver disease and has received all three doses of the Hep A risk Twinrix 3 dose series .,07/25/1966,M,15,Chronic liver disease,,,,,,,,Complete,08/05/2016,Hep A,104,SKB,Valid,risk,,09/02/2016,HepA-HepB,104,SKB,Valid,risk,,02/04/2017,HepA-HepB,104,SKB,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,HepA,02/04/2017,All Valid: Forecast Test,08/01/2016,05/22/2019,Recommended based on Condition,Added description,4
2016-UC-0040,Patient is 26 years of age a Public safety worker exposed to blood or infectious body fluids and has not received the Hepatitis B vaccine.,01/12/1990,M,57,Public safety worker exposed to blood or infection body fluids,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,01/12/2009,01/12/2009,,,HepB,03/12/2016,No Doses Administered,08/09/2016,07/29/2019,Recommended based on Condition,Updated assessment date and Added description,4
2016-UC-0042,Patient is a Public Safety worker and seeks protection and has received the second dose of the Twinrix 4 dose series.,03/29/1983,M,1,Patient seeks protection,,,,,,,,Not Complete,05/17/2016,Hep B,104,SKB,Valid,risk,,05/24/2016,Hep B,104,SKB,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,06/07/2016,06/07/2016,06/15/2016,,HepB,05/24/2016,All Valid: Forecast Test,08/09/2016,05/22/2019,Recommended based on Condition,Updated CVX code to 104 to reflect Twinrix vaccine. Updated observation code to 001,4.1
2016-UC-0043,Patient is a Public Safety worker and seeks protection and has received the third dose of the Twinrix 4 dose series.,03/29/1983,M,1,Patient seeks protection,,,,,,,,Not Complete,05/17/2016,Hep B,104,SKB,Valid,risk,,05/24/2016,Hep B,104,SKB,Valid,risk,,06/07/2016,Hep B,104,SKB,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4,05/17/2017,05/17/2017,,,HepB,06/07/2016,All Valid: Forecast Test,08/09/2016,05/22/2019,Recommended based on Condition,Updated to reflect that the fourth dose of the Risk 4 dose Twinrix series should be forecasted 12 months after the first dose.,4
2016-UC-0044,Patient is a Public safety worker exposed to blood or infectious body fluids and has received all four doses of the accelerated Twinrix 4 dose vaccine series.,06/23/1990,F,57,Public safety worker exposed to blood or infection body fluids,,,,,,,,Complete,05/17/2016,Hep B,104,SKB,Valid,risk,,05/24/2016,Hep B,104,SKB,Valid,risk,,06/07/2016,Hep B,104,SKB,Valid,risk,,06/17/2017,Hep B Adult,104,SKB,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,-,,,,,HepB,06/17/2017,All Valid: Forecast Test,08/09/2016,07/29/2019,Recommended based on Condition,Added description and updated assessment date,4
2016-UC-0045,Patient is 50 years of age unvaccinated and is on dialysis.,01/17/1966,M,32,Dialysis patient,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,01/17/1985,01/17/1985,,,HepB,04/22/2016,No Doses Administered,08/22/2016,07/29/2019,Recommended based on Condition,Added description and updated assessment date,4
2016-UC-0046,Patient is on dialysis and has received the first dose of the Hep B risk Recombivax 3 dose series vaccine.,01/17/1966,M,32,Dialysis patient,,,,,,,,Not Complete,04/22/2016,Hep B Dialysis,44,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,05/20/2016,05/20/2016,,,HepB,04/22/2016,All Valid: Forecast Test,08/22/2016,05/22/2019,Recommended based on Condition,Added description,4
2016-UC-0047,Patient is on dialysis and has received the second dose of the Hep B risk Recombivax 3 dose series vaccine.,01/17/1966,M,32,Dialysis patient,,,,,,,,Not Complete,04/22/2016,Hep B Dialysis,44,MSD,Valid,risk,,05/20/2016,Hep B Dialysis,44,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,10/20/2016,10/20/2016,,,HepB,05/20/2016,All Valid: Forecast Test,08/22/2016,05/22/2019,Recommended based on Condition,Added description,4
2016-UC-0048,Patient is on dialysis and has received all three doses of the Hep B risk Recombivax 3 dose series vaccine.,04/30/1953,F,32,Dialysis patient,,,,,,,,Complete,05/15/2016,Hep B Dialysis,44,MSD,Valid,risk,,06/12/2016,Hep B Dialysis,44,MSD,Valid,risk,,11/12/2016,Hep B Dialysis,44,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,HepB,11/12/2016,All Valid: Forecast Test,08/22/2016,05/22/2019,Recommended based on Condition,Added description,4
2016-UC-0049,Patient is 69 years of age unvaccinated with Hep B and is on dialysis.,02/13/1947,F,32,Dialysis patient,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,02/13/1966,02/13/1966,,,HepB,03/13/2016,No Doses Administered,08/26/2016,07/29/2019,Recommended based on Condition,Updated forecast date to reflect minimum age for dose 1 updated assessment date,4
2016-UC-0050,Patient is on dialysis and has received the first dose of the Hep B risk Engerix- B 4- dose series.,02/13/1947,F,32,Dialysis patient,,,,,,,,Not Complete,03/13/2016,Hep B Adult,43,SKB,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,04/10/2016,04/10/2016,,,HepB,03/13/2016,All Valid: Forecast Test,08/26/2016,05/22/2019,Recommended based on Condition,Added description,4
2016-UC-0051,Patient is on dialysis and has received the second dose of the Hep B risk Engerix- B 4- dose series.,02/13/1947,F,32,Dialysis patient,,,,,,,,Not Complete,03/13/2016,Hep B Adult,43,SKB,Valid,risk,,04/10/2016,Hep B Adult,43,SKB,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,05/08/2016,05/08/2016,,,HepB,04/10/2016,All Valid: Forecast Test,08/26/2016,05/22/2019,Recommended based on Condition,Added description,4
2016-UC-0052,Patient is on dialysis and has received the third dose of the Hep B risk Engerix- B 4- dose series.,02/13/1947,F,32,Dialysis patient,,,,,,,,Not Complete,03/13/2016,Hep B Adult,43,SKB,Valid,risk,,04/10/2016,Hep B Adult,43,SKB,Valid,risk,,05/08/2016,Hep B Adult,43,SKB,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4,09/08/2016,09/08/2016,,,HepB,05/08/2016,All Valid: Forecast Test,08/26/2016,04/08/2019,Recommended based on Condition,Updated forecast date to reflect accurate dose four forecast. Added description,4
2016-UC-0053,Patient is on dialysis and has received all four doses of the Hep B risk Engerix- B 4- dose series.,02/13/1947,F,32,Dialysis patient,,,,,,,,Complete,03/13/2016,Hep B Adult,43,SKB,Valid,risk,,04/10/2016,Hep B Adult,43,SKB,Valid,risk,,05/08/2016,Hep B Adult,43,SKB,Valid,risk,,09/08/2016,Hep B Adult,43,SKB,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,-,,,,,HepB,09/08/2016,All Valid: Forecast Test,08/26/2016,07/29/2019,Recommended based on Condition,Updated to add a valid fourth dose administration. Updated assessment date,4
2016-UC-0054,Patient is 2 years of age has anatomical or functional asplenia and has not received any prior doses of the Hib vaccine.,07/15/2014,F,160,Anatomical or functional asplenia,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,07/15/2015,07/15/2015,,,Hib,07/15/2015,No Doses Administered,08/11/2016,07/29/2019,Recommended based on Condition,Added description updated assessment date,4
2016-UC-0055,Patient is 2 years of age and has anatomical or functional asplenia and has received one dose of the Hib Risk 2 dose series vaccine.,07/15/2014,F,160,Anatomical or functional asplenia,,,,,,,,Not Complete,08/15/2016,PRP-T,48,PMC,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,10/10/2016,10/10/2016,,,Hib,08/15/2016,All Valid: Forecast Test,08/11/2016,07/29/2019,Recommended based on Condition,Added description updated assessment date,4
2016-UC-0056,Patient is 2 years of age and has anatomical or functional asplenia and has received the second dose of the Hib Risk 2 dose series.,07/15/2014,F,160,Anatomical or functional asplenia,,,,,,,,Complete,08/08/2016,PRP-T,48,PMC,Valid,standard,,10/03/2016,PRP-T,48,PMC,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Hib,10/03/2016,All Valid: Forecast Test,08/11/2016,01/07/2019,Recommended based on Condition,Added description,4
2016-UC-0057,Patient is 18 months of age has Persistent complement properdin or factor B deficiency and has received only one dose of the Hib vaccine before 12 months of age.,08/10/2014,F,151,Persistent complement properdin or factor B deficiency,,,,,,,,Not Complete,01/10/2015,PRP-OMP,49,MSD,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,08/10/2015,08/10/2015,,,Hib,01/10/2015,All Valid: Forecast Test,08/25/2016,07/29/2019,Recommended based on Condition,Added description updated assessment date,4
2016-UC-0058,Patient is a child that has Persistent complement properdin or factor B deficiency and has received one dose of the Hib standard vaccine before 12 months of age and one dose of the Hib risk child 2 dose series vaccine.,08/10/2014,F,151,Persistent complement properdin or factor B deficiency,,,,,,,,Not Complete,01/10/2015,PRP-OMP,49,MSD,Valid,standard,,04/13/2016,PRP-OMP,49,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,06/08/2016,06/08/2016,,,Hib,04/13/2016,All Valid: Forecast Test,08/25/2016,05/04/2019,Recommended based on Condition,Updated to display accurate forecasting date based on ACIP recommendations added description,4
2016-UC-0059,Patient is a child that has Persistent complement properdin or factor B deficiency and has received one dose of the Hib standard vaccine before 12 months of age and two doses of the Hib risk child 2 dose series vaccine.,08/10/2014,F,151,Persistent complement properdin or factor B deficiency,,,,,,,,Complete,01/10/2015,PRP-OMP,49,MSD,Valid,standard,,04/13/2016,PRP-OMP,49,MSD,Valid,risk,,06/08/2016,PRP-OMP,49,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Hib,06/08/2016,All Valid: Forecast Test,08/25/2016,04/25/2019,Recommended based on Condition,Added description,4
2016-UC-0060,Patient is 36 months of age has anatomical or functional asplenia and has received two dose of the Standard Hib vaccine before 12 months of age.,04/22/2013,M,160,Anatomical or functional asplenia,,,,,,,,Not Complete,06/10/2013,PRP-T,48,PMC,Valid,standard,,07/08/2013,PRP-T,48,PMC,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,09/02/2013,09/02/2013,,,Hib,07/08/2013,All Valid: Forecast Test,08/11/2016,01/07/2019,Recommended based on Condition,Updated to display accurate forecasting date based on ACIP recommendations,4
2016-UC-0061,Patient is 36 months of age has anatomical or functional asplenia and has received two previous doses of the Standard Hib vaccine before 12 months of age and a dose of the Hib risk child 2 dose series vaccine.,04/22/2013,M,160,Anatomical or functional asplenia,,,,,,,,Complete,06/10/2013,PRP-T,48,PMC,Valid,standard,,07/08/2013,PRP-T,48,PMC,Valid,standard,,05/14/2016,PRP-T,48,PMC,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Hib,05/14/2016,All Valid: Forecast Test,08/11/2016,04/25/2019,Recommended based on Condition,Added description,4
2016-UC-0062,Patient is 7 years of age has not received any Hib vaccine and is undergoing elective splenectomy.,06/22/2009,M,2,Undergoing elective splenectomy,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,09/22/2010,09/22/2010,,Vaccination 14 or more days before splenectomy is suggested.,Hib,07/01/2016,No Doses Administered,08/15/2016,12/02/2019,Recommended based on Condition,Updated earliest and recommended forecast dates to age 15 mos based on childhood recommendations for undergoing elective splenectomy and added description.,4.1
2016-UC-0063,Patient is 7 years and is undergoing elective splenectomy and has received the one dose Hib risk 1 dose series,06/22/2009,M,2,Undergoing elective splenectomy,,,,,,,,Complete,07/01/2016,PRP-OMP,49,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,Vaccination 14 or more days before splenectomy is suggested.,Hib,07/01/2016,All Valid: Forecast Test,08/15/2016,01/07/2019,Recommended based on Condition,Added description,4
2016-UC-0064,Patient is 19 years of age is undergoing elective splenectomy and has no history of receiving Hib vaccine,07/10/1997,F,2,Undergoing elective splenectomy,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,10/10/1998,10/10/1998,,Vaccination 14 or more days before splenectomy is suggested.,Hib,08/03/2016,No Doses Administered,08/15/2016,12/02/2019,Recommended based on Condition,Updated Earliest and Recommended date to reflect 15 mos Added description updated assessment date,4.1
2016-UC-0065,Patient is 19 years of age and undergoing elective splenectomy and has received the Hib risk 1 dose series,07/10/1997,F,2,Undergoing elective splenectomy,,,,,,,,Complete,08/03/2016,PRP-OMP,49,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,Vaccination 14 or more days before splenectomy is suggested.,Hib,08/03/2016,All Valid: Forecast Test,08/15/2016,01/08/2019,Recommended based on Condition,Added description,4
2016-UC-0066,Patient is 12 years of age has HIV infection and unvaccinated with Hib vaccine,04/23/2003,F,155,HIV/AIDS - not severely immunocompromised,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,07/23/2004,07/23/2004,,,Hib,02/03/2016,No Doses Administered,08/23/2016,01/08/2019,Recommended based on Condition,Added description,4
2016-UC-0067,Patient is 12 years of age has HIV infection and has received the Hib risk 1 dose series.,04/23/2003,F,155,HIV/AIDS - not severely immunocompromised,,,,,,,,Complete,02/03/2016,PRP-OMP,49,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Hib,02/03/2016,No Doses Administered,08/23/2016,01/08/2019,Recommended based on Condition,Added description,4
2016-UC-0068,Patient is 4 years of age a recipient of a successful hematopoietic stem cell transplant 6 months ago.,08/14/2010,M,4,Recipient of a hematopoietic stem cell transplant,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,09/25/2010,09/25/2010,,At least 4 weeks should separate doses 6 to 12 months after a successful transplant.,Hib,09/19/2014,No Doses Administered,08/15/2016,01/08/2019,Recommended based on Condition,Added description,4
2016-UC-0069,Patient is a child that is a recipient of a successful hematopoietic stem cell transplant and has a dose of the Hib vaccine.,08/14/2010,M,4,Recipient of a hematopoietic stem cell transplant,,,,,,,,Not Complete,09/19/2014,PRP-T,48,PMC,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,10/17/2014,10/17/2014,,At least 4 weeks should separate doses 6 to 12 months after a successful transplant.,Hib,09/19/2014,All Valid: Forecast Test,08/15/2016,01/08/2019,Recommended based on Condition,Added description,4
2016-UC-0070,Patient is a child and a recipient of a successful hematopoietic stem cell transplant and has received two doses of the Hib risk 3-dose series.,04/09/2006,M,4,Recipient of a hematopoietic stem cell transplant,,,,,,,,Not Complete,09/19/2014,PRP-T,48,PMC,Valid,standard,,10/17/2014,PRP-T,48,PMC,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,11/14/2014,11/14/2014,,At least 4 weeks should separate doses 6 to 12 months after a successful transplant.,Hib,10/17/2014,All Valid: Forecast Test,08/15/2016,01/08/2019,Recommended based on Condition,Added description,4
2016-UC-0071,Patient is a child is a recipient of a successful hematopoietic stem cell transplant and has received all three doses of the Hib risk 3 dose series 6 to 12 months post operation.,05/28/2004,M,4,Recipient of a hematopoietic stem cell transplant,,,,,,,,Complete,06/01/2014,PRP-T,48,PMC,Valid,standard,,06/29/2014,PRP-T,48,PMC,Valid,risk,,07/27/2014,PRP-T,48,PMC,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,At least 4 weeks should separate doses 6 to 12 months after a successful transplant.,Hib,07/27/2014,All Valid: Forecast Test,08/15/2016,01/08/2019,Recommended based on Condition,Added description,4
2016-UC-0072,Patient is 20 years of age and is a recipient of a successful hematopoietic stem cell transplant and has not receive recommended doses of the HIB vaccine.,05/13/1996,M,4,Recipient of a hematopoietic stem cell transplant,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,06/24/1996,06/24/1996,,At least 4 weeks should separate doses 6 to 12 months after a successful transplant.,Hib,07/27/2016,No Doses Administered,08/22/2016,01/09/2019,Recommended based on Condition,Added Vaccine Group Descriptions and forecast date,4
2016-UC-0073,Patient is an adult recipient of a successful hematopoietic stem cell transplant and has received the first dose of the Hib Risk 3 dose series.,05/13/1996,M,4,Recipient of a hematopoietic stem cell transplant,,,,,,,,Not Complete,07/25/2016,PRP-T,48,PMC,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,08/22/2016,08/22/2016,,At least 4 weeks should separate doses 6 to 12 months after a successful transplant.,Hib,07/25/2016,All Valid: Forecast Test,08/22/2016,01/09/2019,Recommended based on Condition,Added description,4
2016-UC-0074,Patient is a adult recipient of a successful hematopoietic stem cell transplant and has received the second dose of the Hib Risk 3 dose series.,05/13/1996,M,4,Recipient of a hematopoietic stem cell transplant,,,,,,,,Not Complete,07/25/2016,PRP-T,48,PMC,Valid,risk,,08/22/2016,PRP-T,48,PMC,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,09/19/2016,09/19/2016,,At least 4 weeks should separate doses 6 to 12 months after a successful transplant.,Hib,08/22/2016,All Valid: Forecast Test,08/25/2016,01/09/2019,Recommended based on Condition,Added description,4
2016-UC-0075,Patient is a adult recipient of a successful hematopoietic stem cell transplant and has received all three doses of the Hib Risk 3 dose series.,05/13/1996,M,4,Recipient of a hematopoietic stem cell transplant,,,,,,,,Complete,07/25/2016,PRP-T,48,PMC,Valid,risk,,08/22/2016,PRP-T,48,PMC,Valid,risk,,09/19/2016,PRP-T,48,PMC,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,At least 4 weeks should separate doses 6 to 12 months after a successful transplant.,Hib,09/19/2016,All Valid: Forecast Test,08/25/2016,01/09/2019,Recommended based on Condition,Added description,4
2016-UC-0076,Patient is 9 years of age female has a history of sexual abuse/assault and has not received the HPV vaccine.,04/04/2007,F,169,History of sexual abuse or assault,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,04/04/2016,04/04/2016,04/03/2018,,HPV,01/09/2017,No Doses Administered,08/15/2016,05/22/2019,Recommended based on Condition,added Past Due date and description,4
2016-UC-0077,Patient is a 9 years of age female has a history of sexual abuse/assault and has received the first dose of the HPV vaccine.,04/04/2007,F,169,History of sexual abuse or assault,,,,,,,,Not Complete,12/15/2016,9vHPV,165,MSD,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,05/15/2017,06/15/2017,02/11/2018,,HPV,12/15/2016,All Valid: Forecast Test,08/15/2016,05/22/2019,Recommended based on Condition,added description,4
2016-UC-0078,Patient is 10 years of age female has a history of sexual abuse/assault and has received the second dose of the HPV risk female 2 dose series at 5 months.,06/30/2006,F,169,History of sexual abuse or assault,,,,,,,,Complete,08/05/2016,9vHPV,165,MSD,Valid,standard,,01/05/2017,9vHPV,165,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,HPV,01/05/2017,All Valid: Forecast Test,08/16/2016,05/04/2019,Not Recommended: Patient Complete,added description,4
2016-UC-0079,Patient is 11 years of age female has a history of sexual abuse/assault and has received two doses of the HPV risk female 2 dose series,03/03/2005,F,169,History of sexual abuse or assault,,,,,,,,Complete,12/19/2016,9vHPV,165,MSD,Valid,standard,,06/01/2017,9vHPV,165,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,HPV,06/01/2017,All Valid: Forecast Test,08/16/2016,01/09/2019,Recommended based on Condition,New HPV 2 dose recommendation added description,4
2016-UC-0080,Patient is 9 years of age male has a history of sexual abuse/assault and has not received the HPV vaccine.,02/15/2007,M,169,History of sexual abuse or assault,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,02/15/2016,02/15/2016,02/14/2018,,HPV,11/17/2016,No Doses Administered,08/16/2016,06/12/2019,Recommended based on Condition,added description,4
2016-UC-0083,Patient is 10 years of age male has a history of T-Lymphocyte  and has received three doses of the HPV risk male 3 dose series vaccine.,03/13/2006,M,148,T-lymphocyte [cell-mediated and humoral] - Partial defects,,,,,,,,Complete,05/17/2016,9vHPV,165,MSD,Valid,standard,,06/14/2016,9vHPV,165,MSD,Valid,risk,,11/01/2016,9vHPV,165,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,HPV,11/01/2016,All Valid: Forecast Test,08/17/2016,01/09/2019,Recommended based on Condition,Update test case with observational code 148. Added description.,4
2016-UC-0084,Patient is 9 years of age male has a history of sexual abuse/assault and has received the 2nd dose of the Risk Male 2 dose HPV vaccine at 4 weeks.,01/13/2007,M,169,History of sexual abuse or assault,,,,,,,,Not Complete,04/21/2016,9vHPV,165,MSD,Valid,standard,,05/19/2016,9vHPV,165,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,09/21/2016,10/21/2016,06/17/2017,,HPV,05/19/2016,All Valid: Forecast Test,08/17/2016,05/04/2019,Recommended based on Condition,added description,4
2016-UC-0085,Patient is an adult male MSM and has no previous history of the HPV vaccine.,02/02/1994,M,36,Men who have sex with men,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,02/02/2003,02/02/2005,03/01/2007,,HPV,02/02/2016,All Valid: Forecast Test,08/17/2016,01/09/2019,Recommended based on Condition,Updated Earliest Recommended and Past due dates added description,4
2016-UC-0086,Patient is an adult male MSM and has received his first dose of the HPV vaccine.,02/02/1994,M,36,Men who have sex with men,,,,,,,,Not Complete,07/21/2016,9vHPV,165,MSD,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,08/18/2016,08/18/2016,11/09/2016,,HPV,07/21/2016,All Valid: Forecast Test,08/17/2016,01/09/2019,Recommended based on Condition,Updated Earliest Recommended Past due dates and added description.,4
2016-UC-0087,Patient is an adult male MSM and has received the second dose of the HPV risk adult male 3 dose series.,01/23/1988,M,36,Men who have sex with men,,,,,,,,Not Complete,04/03/2014,4vHPV,62,MSD,Valid,standard,,05/01/2014,4vHPV,62,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,09/03/2014,10/03/2014,11/30/2014,,HPV,05/01/2014,All Valid: Forecast Test,08/18/2016,01/09/2019,Recommended based on Condition,Updated Earliest Recommended and past due date based on HPV Recommendations added description,4
2016-UC-0088,Patient is an adult male MSM and has received all three doses of the HPV risk adult male 3-dose series.,03/01/1990,M,36,Men who have sex with men,,,,,,,,Complete,03/28/2015,4vHPV,62,MSD,Valid,standard,,04/25/2015,4vHPV,62,MSD,Valid,risk,,09/14/2015,4vHPV,62,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,HPV,09/14/2015,All Valid: Forecast Test,08/18/2016,01/09/2019,Recommended based on Condition,Added description,4
2016-UC-0089,Patient is 32 years of age and plans on traveling to an endemic area (for longer than a month) with Japanese encephalitis.,07/01/1984,F,165,Longer-term (e.g. 1 month or more) travel to a JE-endemic area,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,09/01/1984,09/01/1984,,ACIP recommends that if the primary series of JE-VC was administered greater than 1 year previously a booster dose may be given before potential JE virus exposure. ACIP recommendations should be consulted for information on prevention of JE and settings in which JE vaccine is recommended can be considered or is not recommended. Data on the response to a booster dose administered greater than 2 years after the primary series of JE-VC are not available. Data on the need for and timing of additional booster doses also are not available.  This includes long-term travelers ≥1 month recurrent travelers or expatriates who will be based in urban areas but are likely to visit endemic rural or agricultural areas during a high-risk period of JE virus transmission.JE vaccine should be considered for short-term (less than 1 month) travelers whose itinerary or activities might increase their risk for exposure to JE virus. JE vaccine is not recommended for short-term travelers whose visit will be restricted to urban areas. The series should be completed ≥1 week before travel.,Japanese Encephalitis,08/15/2016,No Doses Administered,08/23/2016,05/04/2019,Recommended based on Condition,Added description,4
2016-UC-0090,Patient is an adult traveling to an endemic area with Japanese Encephalitis for longer than a month and has received the first dose of the Japanese Encephalitis risk 2 dose series vaccine.,07/01/1984,F,165,Longer-term (e.g. 1 month or more) travel to a JE-endemic area,,,,,,,,Not Complete,08/15/2016,Japanese Encephalitis VC,134,VAL,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,08/22/2016,08/22/2016,09/11/2016,ACIP recommends that if the primary series of JE-VC was administered greater than 1 year previously a booster dose may be given before potential JE virus exposure. ACIP recommendations should be consulted for information on prevention of JE and settings in which JE vaccine is recommended can be considered or is not recommended. Data on the response to a booster dose administered greater than 2 years after the primary series of JE-VC are not available. Data on the need for and timing of additional booster doses also are not available.  This includes long-term travelers ≥1 month recurrent travelers or expatriates who will be based in urban areas but are likely to visit endemic rural or agricultural areas during a high-risk period of JE virus transmission.JE vaccine should be considered for short-term (less than 1 month) travelers whose itinerary or activities might increase their risk for exposure to JE virus. JE vaccine is not recommended for short-term travelers whose visit will be restricted to urban areas. The series should be completed ≥1 week before travel.,Japanese Encephalitis,08/15/2016,All Valid: Forecast Test,08/23/2016,12/02/2019,Recommended based on Condition,Updated earliest and recommended dates to 7 days. Added description,4.1
2016-UC-0091,Patient is an adult traveling to an endemic area with Japanese Encephalitis for longer than a month and has received the second dose of the Japanese Encephalitis risk 2 dose series vaccine.,09/10/1983,M,165,Longer-term (e.g. 1 month or more) travel to a JE-endemic area,,,,,,,,Not Complete,04/28/2016,Japanese Encephalitis VC,134,VAL,Valid,risk,,05/25/2016,Japanese Encephalitis VC,134,VAL,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,05/25/2017,05/25/2017,,ACIP recommends that if the primary series of JE-VC was administered greater than 1 year previously a booster dose may be given before potential JE virus exposure. ACIP recommendations should be consulted for information on prevention of JE and settings in which JE vaccine is recommended can be considered or is not recommended. Data on the response to a booster dose administered greater than 2 years after the primary series of JE-VC are not available. Data on the need for and timing of additional booster doses also are not available.  This includes long-term travelers ≥1 month recurrent travelers or expatriates who will be based in urban areas but are likely to visit endemic rural or agricultural areas during a high-risk period of JE virus transmission.JE vaccine should be considered for short-term (less than 1 month) travelers whose itinerary or activities might increase their risk for exposure to JE virus. JE vaccine is not recommended for short-term travelers whose visit will be restricted to urban areas. The series should be completed ≥1 week before travel.,Japanese Encephalitis,07/10/2019,All Valid: Forecast Test,08/23/2016,07/19/2019,Recommended based on Condition,Added description updated based on new MMWR July 2019 recommendations for booster dose.,4
2016-UC-0092,Patient is 6 months of age and plans to travel with parent from the U.S. for international travel and has not received the Measles (MMR) vaccine.,02/28/2016,F,48,Travelling Internationally,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,08/28/2016,08/28/2016,02/27/2017,,MMR,08/28/2016,No Doses Administered,08/28/2016,04/25/2019,Recommended based on Condition,added description.,4
2016-UC-0093,Patient is 6 months of age and is still traveling with parents from the U.S. for international travel and has received the Measles (MMR) risk 1-dose vaccine series.,02/28/2016,F,48,Travelling Internationally,,,,,,,,Not Complete,08/28/2016,MMR,3,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,02/28/2017,02/28/2017,07/25/2017,Children who received MMR vaccine before age 12 months should be considered potentially susceptible to all three diseases and should be revaccinated with 2 doses of MMR vaccine the first dose administered when the child is aged 12 through 15 months (12 months if the child remains in an area where disease risk is high) and the second dose at least 28 days later.,MMR,08/28/2016,All Valid: Forecast Test,08/18/2016,04/25/2019,Recommended based on Condition,added description,4
2016-UC-0094,Patient is an adult with perinatal HIV infection who does not have evidence of severe immunosuppression and who was vaccinated with MMR before establishment of antiviral therapy,05/12/1996,F,26,Persons with perinatal HIV infection who do not have evidence of severe immunosuppression and who were vaccinated with MMR before establishment of antiviral therapy [ART],,120,Begin Date of antiviral therapy [ART],06/12/2016,,,,Not Complete,05/12/1997,MMR,3,MSD,Valid,standard,,05/12/2000,MMR,3,MSD,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,12/12/2016,12/12/2016,,,MMR,06/12/2016,All Valid: Forecast Test,08/18/2016,03/28/2019,Recommended based on Condition,added description,4
2016-UC-0095,Patient is an adult with perinatal HIV infection who does not have evidence of severe immunosuppression and who was vaccinated with MMR before establishment of antiviral therapy who has received his first dose of the second round of MMR vaccines.,05/12/1996,F,26,Persons with perinatal HIV infection who do not have evidence of severe immunosuppression and who were vaccinated with MMR before establishment of antiviral therapy [ART],,120,Begin Date of antiviral therapy [ART],06/12/2016,,,,Not Complete,05/12/1997,MMR,3,MSD,Valid,standard,,05/12/2000,MMR,3,MSD,Valid,standard,,12/12/2016,MMR,3,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4,07/10/2016,07/10/2016,,,MMR,12/12/2016,All Valid: Forecast Test,08/18/2016,10/30/2019,Recommended based on Condition,Updated title and description of test case.,4.1
2016-UC-0096,Patient is an adult with perinatal HIV infection who does not have evidence of severe immunosuppression and who was vaccinated with MMR before establishment of antiviral therapy and has received the second dose of the second round of MMR vaccine.,05/12/1996,F,26,Persons with perinatal HIV infection who do not have evidence of severe immunosuppression and who were vaccinated with MMR before establishment of antiviral therapy [ART],,120,Begin Date of antiviral therapy [ART],06/12/2016,,,,Complete,05/12/1997,MMR,3,MSD,Valid,standard,,05/12/2000,MMR,3,MSD,Valid,standard,,12/12/2016,MMR,3,MSD,Valid,risk,,01/12/2017,MMR,3,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,-,,,,,MMR,01/12/2017,All Valid: Forecast Test,08/18/2016,10/30/2019,Recommended based on Condition,Updated title and description of test case.,4.1
2016-UC-0097,Patient is 18 years of age and is seeking protection against strains of Men B disease.,07/04/1998,M,1,Patient seeks protection,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,07/04/2008,07/04/2008,,,MenB,07/04/2016,No Doses Administered,07/04/2016,04/25/2019,Recommended based on Condition,added description,4
2016-UC-0098,Patient is 18 years of age and is seeking protection against strains of Men B disease and has received the first dose of the Men B series.,07/04/1998,M,1,Patient seeks protection,,,,,,,,Not Complete,07/04/2016,meningococcal B OMV,163,PFR,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,08/01/2016,08/01/2016,,,MenB,07/04/2016,All Valid: Forecast Test,08/18/2016,03/07/2019,Recommended based on Condition,added description,4
2016-UC-0099,Patient is 18 years of age and seeking protection against strains of Men B disease and has received the second dose of the Men B dose vaccine series.,07/04/1998,M,1,Patient seeks protection,,,,,,,,Complete,07/04/2016,meningococcal B OMV,163,PFR,Valid,risk,,01/04/2017,meningococcal B OMV,163,PFR,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,MenB,01/04/2017,All Valid: Forecast Test,01/04/2017,03/07/2019,Recommended based on Condition,added description,4
2016-UC-0100,Patient is 10 years of age has anatomical or functional asplenia and has not received the Meningococcal B vaccine.,03/28/2006,M,160,Anatomical or functional asplenia,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,03/28/2016,03/28/2016,,,MenB,03/28/2016,No Doses Administered,08/30/2016,01/10/2019,Recommended based on Condition,Added description,4
2016-UC-0101,Patient is 10 years of age has anatomical or functional asplenia and has received the first dose of the Men B risk 2-dose vaccine.,03/28/2006,M,160,Anatomical or functional asplenia,,,,,,,,Not Complete,03/28/2016,meningococcal B OMV,163,NOV,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,04/25/2016,04/25/2016,,,MenB,03/28/2016,All Valid: Forecast Test,08/30/2016,01/10/2019,Recommended based on Condition,Added description,4
2016-UC-0103,Patient is a microbiologist routinely exposed to Neisseria Meningitidis.,10/01/1976,F,50,Microbiologists routinely exposed to Neisseria meningitidis,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,10/01/1986,10/01/1986,,,MenB,06/23/2016,No Doses Administered,09/07/2016,01/10/2019,Recommended based on Condition,Added description,4
2016-UC-0104,Patient is a microbiologist routinely exposed to Neisseria Meningitidis and has received the first dose of the Men B vaccine,10/01/1976,F,50,Microbiologists routinely exposed to Neisseria meningitidis,,,,,,,,Not Complete,06/23/2016,meningococcal B recombinant,162,PFR,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,07/21/2016,07/21/2016,08/17/2016,,MenB,06/23/2016,All Valid: Forecast Test,09/07/2016,12/02/2019,Recommended based on Condition,Added past due date.  Updated based on change in version 3.4. Dose 2 can be administered at 4 weeks - 4 days 4 weeks added description.,4.1
2016-UC-0105,Microbiologist routinely exposed to Neisseria Meningitidis and has received the second dose of the Men B risk 3 dose series,10/01/1976,F,50,Microbiologists routinely exposed to Neisseria meningitidis,,,,,,,,Not Complete,06/23/2016,meningococcal B recombinant,162,PFR,Valid,risk,,07/21/2016,meningococcal B recombinant,162,PFR,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,12/23/2016,12/23/2016,,,MenB,07/21/2016,All Valid: Forecast Test,09/07/2016,12/02/2019,Recommended based on Condition,Updated Earliest and Recommended dates added description,4.1
2016-UC-0107,8 week old infant with anatomical or functional asplenia and has not received Meningococcal vaccine.,02/14/2015,M,160,Anatomical or functional asplenia,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,04/14/2015,04/14/2015,,If MenACWY-D is used it should be administered at least 4 weeks after completion of all PCV doses.,Meningococcal,04/14/2015,No Doses Administered,09/07/2016,01/10/2019,Recommended based on Condition,Added description,4
2016-UC-0108,Patient is an infant with functional asplenia and has received the first dose of the Meningococcal ACWY risk start before 7 months series.,02/14/2015,M,160,Anatomical or functional asplenia,,,,,,,,Not Complete,04/14/2015,Meningococcal MCV4O,136,NOV,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,06/09/2015,06/09/2015,,If MenACWY-D is used it should be administered at least 4 weeks after completion of all PCV doses.,Meningococcal,04/14/2015,All Valid: Forecast Test,09/07/2016,01/11/2019,Recommended based on Condition,Added description,4
2016-UC-0109,Patient is an infant with functional asplenia and has received the second dose of the Meningococcal ACWY risk start before 7 months series.,02/14/2015,M,160,Anatomical or functional asplenia,,,,,,,,Not Complete,04/14/2015,Meningococcal MCV4O,136,NOV,Valid,risk,,06/09/2015,Meningococcal MCV4O,136,NOV,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,08/04/2015,08/04/2015,,If MenACWY-D is used it should be administered at least 4 weeks after completion of all PCV doses.,Meningococcal,06/09/2015,All Valid: Forecast Test,09/07/2016,01/14/2019,Recommended based on Condition,Added description,4
2016-UC-0110,Patient is an infant with functional asplenia and has receive the third dose of the Meningococcal ACWY risk start before 7 months 4-dose series.,02/14/2015,M,160,Anatomical or functional asplenia,,,,,,,,Not Complete,04/14/2015,Meningococcal MCV4O,136,NOV,Valid,risk,,06/09/2015,Meningococcal MCV4O,136,NOV,Valid,risk,,08/04/2015,Meningococcal MCV4O,136,NOV,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4,02/04/2016,02/04/2016,,If MenACWY-D is used it should be administered at least 4 weeks after completion of all PCV doses.,Meningococcal,08/04/2015,All Valid: Forecast Test,09/08/2016,01/14/2019,Recommended based on Condition,Added description,4
2016-UC-0111,Patient is an 12 month old infant with functional asplenia and has received all four doses of the Meningococcal ACWY risk start before 7 months series.,02/14/2015,M,160,Anatomical or functional asplenia,,,,,,,,Not Complete,04/14/2015,Meningococcal MCV4O,136,NOV,Valid,risk,,06/09/2015,Meningococcal MCV4O,136,NOV,Valid,risk,,08/04/2015,Meningococcal MCV4O,136,NOV,Valid,risk,,02/14/2016,Meningococcal MCV4O,136,NOV,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,5,02/14/2019,02/14/2019,,If MenACWY-D is used it should be administered at least 4 weeks after completion of all PCV doses.,Meningococcal,02/14/2016,All Valid: Forecast Test,09/08/2016,01/14/2019,Recommended based on Condition,Added description,4
2016-UC-0112,Patient is a 4 year old child who has functional asplenia has completed the primary doses and has received the first booster dose at 3 years later.,08/23/2012,M,160,Anatomical or functional asplenia,,,,,,,,Not Complete,10/23/2012,Meningococcal MCV4O,136,NOV,Valid,risk,,12/18/2012,Meningococcal MCV4O,136,NOV,Valid,risk,,02/12/2013,Meningococcal MCV4O,136,NOV,Valid,risk,,08/23/2013,Meningococcal MCV4O,136,NOV,Valid,risk,,08/23/2016,Meningococcal MCV4O,136,NOV,Valid,risk,,,,,,,,,,,,,,,,6,08/23/2021,08/23/2021,,If MenACWY-D is used it should be administered at least 4 weeks after completion of all PCV doses.,Meningococcal,08/23/2016,All Valid: Forecast Test,09/08/2016,01/14/2019,Recommended based on Condition,Added description,4
2016-UC-0113,Patient is a 9 year old child who has functional asplenia and has received the 3 year booster dose as well as the 5 year booster dose of the Meningococcal ACWY risk start before 7 months series.,01/01/2007,M,160,Anatomical or functional asplenia,,,,,,,,Not Complete,03/01/2007,Meningococcal MCV4O,136,NOV,Valid,risk,,04/26/2007,Meningococcal MCV4O,136,NOV,Valid,risk,,06/21/2007,Meningococcal MCV4O,136,NOV,Valid,risk,,01/01/2008,Meningococcal MCV4O,136,NOV,Valid,risk,,01/01/2011,Meningococcal MCV4O,136,NOV,Valid,risk,,01/01/2016,Meningococcal MCV4O,136,NOV,Valid,risk,,,,,,,,,7,01/01/2021,01/01/2021,,If MenACWY-D is used it should be administered at least 4 weeks after completion of all PCV doses.,Meningococcal,01/01/2016,All Valid: Forecast Test,09/08/2016,01/14/2019,Recommended based on Condition,Added Description,4
2016-UC-0114,7 month old infant (with no previous history of Meningococcal vaccine) at risk for Meningococcal disease during a community outbreak.,05/10/2015,F,70,Persons at risk during an outbreak,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,12/10/2015,12/10/2015,,If MenACWY-D is used it should be administered at least 4 weeks after completion of all PCV doses.,Meningococcal,12/10/2015,No Doses Administered,09/08/2016,01/14/2019,Recommended based on Condition,Added Description,4
2016-UC-0115,Patient is a 7 month old infant and is at risk during a community outbreak of Meningococcal disease and has received the first dose of the Meningococcal ACWY risk start after 7 months 2 dose vaccine.,05/10/2015,F,70,Persons at risk during an outbreak,,,,,,,,Not Complete,12/10/2015,Meningococcal MCV4O,136,NOV,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,03/03/2016,03/03/2016,,If MenACWY-D is used it should be administered at least 4 weeks after completion of all PCV doses.,Meningococcal,12/10/2015,All Valid: Forecast Test,09/09/2016,01/14/2019,Recommended based on Condition,Added description,4
2016-UC-0116,Patient is a 12 months old and was at risk during a community outbreak of Meningococcal disease and has received the second dose of the Meningococcal ACWY risk start after 7 months 2 dose vaccine.,05/10/2015,F,70,Persons at risk during an outbreak,,,,,,,,Not Complete,12/10/2015,Meningococcal MCV4O,136,NOV,Valid,risk,,05/10/2016,Meningococcal MCV4O,136,,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,05/10/2019,05/10/2019,,If MenACWY-D is used it should be administered at least 4 weeks after completion of all PCV doses.,Meningococcal,05/10/2016,All Valid: Forecast Test,09/09/2016,01/10/2019,Recommended based on Condition,added description,4
2016-UC-0117,2 month old infant with persistent complement deficiencies and has not received any Meningococcal vaccine.,07/28/2015,M,151,Persistent complement properdin or factor B deficiency,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,09/28/2015,09/28/2015,,If MenACWY-D is used it should be administered at least 4 weeks after completion of all PCV doses.,Meningococcal,09/30/2015,No Doses Administered,09/09/2016,12/02/2019,Recommended based on Condition,Updated Assessment Date. Added description,4.1
2016-UC-0123,Adult with no known history of meningococcal vaccination and has anatomical or functional asplenia,04/18/1992,M,160,Anatomical or functional asplenia,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,04/18/1994,04/18/1994,,If MenACWY-D is used it should be administered at least 4 weeks after completion of all PCV doses.,Meningococcal,05/02/2016,All Valid: Forecast Test,09/09/2016,01/15/2019,Recommended based on Condition,Added description,4
2016-UC-0124,Patient is and adult with anatomical or functional asplenia and has received the first dose of the Meningococcal ACWY risk 2 dose series vaccine,04/18/1992,M,160,Anatomical or functional asplenia,,,,,,,,Not Complete,05/02/2016,Meningococcal MCV4O,136,NOV,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,06/27/2016,06/27/2016,07/24/2016,If MenACWY-D is used it should be administered at least 4 weeks after completion of all PCV doses.,Meningococcal,05/02/2016,All Valid: Forecast Test,09/09/2016,03/07/2019,Recommended based on Condition,added description,4
2016-UC-0125,Patient is an adult with anatomical or functional asplenia and has received the second dose of the Meningococcal ACWY risk 2 dose series vaccines.,04/18/1992,M,160,Anatomical or functional asplenia,,,,,,,,Not Complete,05/02/2016,Meningococcal MCV4O,136,NOV,Valid,risk,,06/27/2016,Meningococcal MCV4O,136,NOV,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,06/27/2021,06/27/2021,,If MenACWY-D is used it should be administered at least 4 weeks after completion of all PCV doses.,Meningococcal,06/27/2016,All Valid: Forecast Test,09/09/2016,03/07/2019,Recommended based on Condition,Added description,4
2016-UC-0127,Patient is a first year college student living in a residence hall and has received the Meningococcal ACWY risk 1 dose series.,01/17/1997,F,46,College students living in residence halls,,,,,,,,Complete,01/17/2016,Meningococcal MCV4P,114,PMC,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Meningococcal,01/17/2016,All Valid: Forecast Test,08/30/2016,03/07/2019,Recommended based on Condition,added description,4
2016-UC-0128,Patient is 60 years of age (vaccine naïve) and at risk during a Meningococcal outbreak.,03/07/1956,M,70,Persons at risk during an outbreak,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,03/07/1958,03/07/1958,,Meningococcal vaccines that are licensed for use in person aged ≥56 year are not currently available in the United States  Persons aged ≥56 years who are recommended meningococcal vaccination because they are at increased risk for meningococcal disease should receive MenACWY conjugate vaccine,Meningococcal,08/30/2016,No Doses Administered,08/30/2016,03/22/2019,Recommended based on Condition, added description,4
2016-UC-0129,Patient is 60 years of age at risk during a Meningococcal outbreak and has received the Meningococcal risk 1 dose vaccine.,03/07/1956,M,70,Persons at risk during an outbreak,,,,,,,,Not Complete,05/23/2016,Meningococcal MPSV4,32,PMC,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,05/23/2021,05/23/2021,,Meningococcal vaccines that are licensed for use in person aged ≥56 year are not currently available in the United States  Persons aged ≥56 years who are recommended meningococcal vaccination because they are at increased risk for meningococcal disease should receive MenACWY conjugate vaccine,Meningococcal,05/23/2016,All Valid: Forecast Test,08/30/2016,03/22/2019,Recommended based on Condition,added description.,4
2016-UC-0130,Patient is pregnant and at 27 weeks of gestation and has not received the Pertussis vaccine (Tdap),06/23/1988,F,7,Pregnant,,170,Onset of pregnancy,08/22/2016,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,02/27/2016,05/01/2017,Administer during each pregnancy (preferably during 27 to 36 weeks’ gestation) regardless of interval since prior Td or Tdap vaccination.,Tdap,08/22/2016,No Doses Administered,08/23/2016,03/28/2019,Recommended based on Condition,added description,4
2016-UC-0131,Patient is pregnant at 27 weeks of gestation and has received a Tdap,06/23/1988,F,7,Pregnant,,170,Onset of pregnancy,08/22/2016,,,,Complete,03/01/2017,Tdap,115,SKB,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,Administer during each pregnancy (preferably during 27 to 36 weeks’ gestation) regardless of interval since prior Td or Tdap vaccination.,Tdap,03/01/2017,All Valid: Forecast Test,08/23/2016,03/28/2019,Recommended based on Condition,added description,4
2016-UC-0132,Laboratory worker who handles specimens that might contain Polio and has completed a Polio standard series but has not received any additional doses.,11/23/1977,M,54,Laboratory workers who handle specimens that might contain polioviruses,,,,,,,,Not Complete,01/23/1978,IPV,10,PMC,Valid,standard,,02/20/1978,IPV,10,PMC,Valid,standard,,11/23/1978,IPV,10,PMC,Valid,standard,,02/02/1982,IPV,10,PMC,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,5,11/23/1995,11/23/1995,11/23/1995,,IPOL,04/04/2016,All Valid: Forecast Test,08/19/2016,01/15/2019,Recommended based on Condition,Added description and Updated past due date,4
2016-UC-0133,Patient is a laboratory worker who handles specimens that might contain Polio and has completed a Polio standard dose series and the additional risk dose.,11/23/1977,M,54,Laboratory workers who handle specimens that might contain polioviruses,,,,,,,,Complete,01/23/1978,IPV,10,PMC,Valid,standard,,02/20/1978,IPV,10,PMC,Valid,standard,,11/23/1978,IPV,10,PMC,Valid,standard,,02/02/1982,IPV,10,PMC,Valid,standard,,04/04/2016,IPV,10,PMC,Valid,standard,,,,,,,,,,,,,,,,-,,,,,IPOL,04/04/2016,All Valid: Forecast Test,08/19/2016,01/15/2019,Recommended based on Condition,Updated test case description and first dose administration to match more closely to the recommendations for adults at risk for polio and added description,4
2016-UC-0134,Patient is 55 years of age with no previous history of the polio vaccine and plans on traveling to areas or countries where polio is endemic.,08/10/1961,F,143,Travel to areas or countries where polio is epidemic or endemic,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,08/10/1979,08/10/1979,,,IPOL,09/05/2016,No Doses Administered,09/05/2016,01/15/2019,Recommended based on Condition,Added description,4
2016-UC-0135,Patient is traveling to areas or countries where polio is endemic and has received the first dose of the polio risk adult vaccine.,08/10/1961,F,143,Travel to areas or countries where polio is epidemic or endemic,,,,,,,,Not Complete,09/05/2016,IPV,10,PMC,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,10/03/2016,10/03/2016,10/30/2016,,IPOL,09/05/2016,All Valid: Forecast Test,08/19/2016,01/15/2019,Recommended based on Condition,Added Past Due date added description,4
2016-UC-0136,Patient is traveling to areas or countries where polio is endemic and has received the second dose of the polio risk adult vaccine.,08/10/1961,F,143,Travel to areas or countries where polio is epidemic or endemic,,,,,,,,Not Complete,09/05/2016,IPV,10,PMC,Valid,risk,,10/03/2016,IPV,10,PMC,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,04/03/2017,04/03/2017,10/02/2017,,IPOL,10/03/2016,All Valid: Forecast Test,08/19/2016,01/15/2019,Recommended based on Condition,Added Past Due date added description,4
2016-UC-0137,Patient is traveling to areas or countries where polio is an epidemic and has received all three doses of the polio risk adult vaccine.,08/10/1961,F,143,Travel to areas or countries where polio is epidemic or endemic,,,,,,,,Complete,09/05/2016,IPV,10,PMC,Valid,risk,,10/03/2016,IPV,10,PMC,Valid,risk,,04/03/2017,IPV,10,PMC,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,IPOL,04/03/2017,All Valid: Forecast Test,08/19/2016,01/15/2019,Recommended based on Condition,Added description,4
2016-UC-0138,Patient is a Rabies Researcher with previous history of Rabies vaccine but has been tested and found to have a fallen serum titer.,02/16/1982,F,53,Rabies researchers,,,,,,,,Not Complete,06/28/2015,Rabies intramuscular injection,175,NOV,Valid,risk,,07/05/2015,Rabies intramuscular injection,175,NOV,Valid,risk,,07/19/2015,Rabies intramuscular injection,175,NOV,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4,01/19/2016,01/19/2016,,The 6 month booster should only be given after a serum sample has been tested for rabies virus neutralizing antibody. The booster should be administered if the serum titer fails to maintain a value of at least complete neutralization of a 1:5 serum dilution by rapid fluorescent focus inhibition test.,Rabies,07/19/2015,All Valid: Forecast Test,08/26/2016,01/15/2019,Recommended based on Condition,Added description,4
2016-UC-0139,Patient is a Rabies Researcher with previous history of Rabies vaccine but has a confirmed test of a fallen serum titer and has received a booster dose of the Rabies risk 3-dose continuous series.,02/16/1982,F,53,Rabies researchers,,,,,,,,Not Complete,06/28/2015,Rabies intramuscular injection,175,NOV,Valid,risk,,07/05/2015,Rabies intramuscular injection,175,NOV,Valid,risk,,07/19/2015,Rabies intramuscular injection,175,NOV,Valid,risk,,01/19/2016,Rabies intramuscular injection,175,NOV,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,5,07/19/2016,07/19/2016,,The 6 month booster should only be given after a serum sample has been tested for rabies virus neutralizing antibody. The booster should be administered if the serum titer fails to maintain a value of at least complete neutralization of a 1:5 serum dilution by rapid fluorescent focus inhibition test.,Rabies,01/19/2016,All Valid: Forecast Test,08/26/2016,01/16/2019,Recommended based on Condition,Updated forecast date to reflect dose #5 at 6 months added description.,4
2016-UC-0140,New Rabies Researcher with no previous history of the Rabies vaccine.,09/21/1986,M,53,Rabies researchers,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,09/21/1986,09/21/1986,,,Rabies,05/16/2016,No Doses Administered,08/26/2016,01/16/2019,Recommended based on Condition,Updated forecast dates to reflect an indication begin age of 18 for the risk added description.,4
2016-UC-0141,Patient is a new Rabies Researcher and has received the first dose of the Rabies risk 3-dose continuous vaccine series.,09/21/1986,M,53,Rabies researchers,,,,,,,,Not Complete,05/16/2016,Rabies intramuscular injection,175,PMC,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,05/23/2016,05/23/2016,,,Rabies,05/16/2016,All Valid: Forecast Test,08/26/2016,01/16/2019,Recommended based on Condition,added CVX code 175 added description,4
2016-UC-0142,Patient is a new Rabies Researcher and has received the second dose of the Rabies risk 3-dose continuous vaccine series.,09/21/1986,M,53,Rabies researchers,,,,,,,,Not Complete,05/16/2016,Rabies intramuscular injection,175,PMC,Valid,risk,,05/23/2016,Rabies intramuscular injection,175,PMC,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,06/06/2016,06/06/2016,06/12/2016,,Rabies,05/23/2016,All Valid: Forecast Test,08/26/2016,01/16/2019,Recommended based on Condition,Updated Past Due date added description,4
2016-UC-0143,Patient is a new Rabies Researcher and has received all three doses of the Rabies risk 3-dose continuous vaccine series.,09/21/1986,M,53,Rabies researchers,,,,,,,,Not Complete,05/16/2016,Rabies intramuscular injection,175,PMC,Valid,risk,,05/23/2016,Rabies intramuscular injection,175,PMC,Valid,risk,,06/06/2016,Rabies intramuscular injection,175,PMC,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4,12/06/2016,12/06/2016,,The 6 month booster should only be given after a serum sample has been tested for rabies virus neutralizing antibody. The booster should be administered if the serum titer fails to maintain a value of at least complete neutralization of a 1:5 serum dilution by rapid fluorescent focus inhibition test.,Rabies,06/06/2016,All Valid: Forecast Test,08/29/2016,01/16/2019,Recommended based on Condition,Updated test case to forecast a fourth dose at 6 months added description.,4
2016-UC-0144,Patient is an animal handler with previous history of the Rabies vaccine but has been tested and found to have a fallen serum titer.,01/12/1990,F,61,Animal handlers,,,,,,,,Not Complete,06/18/2015,Rabies intramuscular injection,175,PMC,Valid,risk,,06/25/2015,Rabies intramuscular injection,175,PMC,Valid,risk,,07/09/2015,Rabies intramuscular injection,175,PMC,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4,07/09/2017,07/09/2017,,The 2 year booster should only be given after a serum sample has been tested for rabies virus neutralizing antibody. The booster should be administered if the serum titer fails to maintain a value of at least complete neutralization of a 1:5 serum dilution by rapid fluorescent focus inhibition test.,Rabies,07/09/2015,All Valid: Forecast Test,08/29/2016,01/16/2019,Recommended based on Condition,added description,4
2016-UC-0145,Animal handler with previous history of the Rabies vaccine but has been tested and found to have a fallen serum titer and has received the booster dose of the Rabies risk 3 dose frequent series.,01/12/1990,F,61,Animal handlers,,,,,,,,Not Complete,06/18/2015,Rabies intramuscular injection,175,PMC,Valid,risk,,06/25/2015,Rabies intramuscular injection,175,PMC,Valid,risk,,07/09/2015,Rabies intramuscular injection,175,PMC,Valid,risk,,07/19/2017,Rabies intramuscular injection,175,PMC,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,5,07/19/2019,07/19/2019,,The 2 year booster should only be given after a serum sample has been tested for rabies virus neutralizing antibody. The booster should be administered if the serum titer fails to maintain a value of at least complete neutralization of a 1:5 serum dilution by rapid fluorescent focus inhibition test.,Rabies,07/19/2017,All Valid: Forecast Test,08/29/2016,03/07/2019,Recommended based on Condition,added description,4
2016-UC-0146,Patient is 46 years of age and travelling to an area at risk of exposure to S. Typhi.,04/19/1970,M,163,Travel to areas in which there is a recognized risk of exposure to S. typhi,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,04/19/1972,04/19/1972,,,Typhoid,07/22/2016,No Doses Administered,08/19/2016,03/07/2019,Recommended based on Condition,added description.,4
2016-UC-0147,Patient is traveling to an area at risk of exposure to S. Typhi and has received the Typhoid risk 1 dose vaccine series two weeks before potential exposure.,04/19/1970,M,163,Travel to areas in which there is a recognized risk of exposure to S. typhi,,,,,,,,Not Complete,07/22/2016,Typhoid capsular polysaccharide,101,PMC,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,07/22/2018,07/22/2018,,This vaccine should be given at least 2 weeks before potential exposure.  Primary vaccination with live-attenuated Ty21a vaccine consists of one enteric-coated capsule taken on alternate days (day 0 2 4 and 6) for a total of four capsules. The capsules must be kept refrigerated (not frozen). Each capsule should be taken with cool water no warmer than 98.6°F (37.0°C) approximately 1 hour before a meal. All doses should be completed at least 1 week before potential exposure.,Typhoid,07/22/2016,All Valid: Forecast Test,08/19/2016,01/16/2019,Recommended based on Condition,Added description,4
2016-UC-0148,Two years later patient continues to travel to an area at risk of exposure to S. Typhi and has received the booster dose of the Typhoid risk 1-dose series.,04/19/1970,M,163,Travel to areas in which there is a recognized risk of exposure to S. typhi,,,,,,,,Not Complete,07/22/2016,Typhoid capsular polysaccharide,101,PMC,Valid,risk,,07/22/2018,Typhoid capsular polysaccharide,101,PMC,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,07/22/2020,07/22/2020,,This vaccine should be given at least 2 weeks before potential exposure.  Primary vaccination with live-attenuated Ty21a vaccine consists of one enteric-coated capsule taken on alternate days (day 0 2 4 and 6) for a total of four capsules. The capsules must be kept refrigerated (not frozen). Each capsule should be taken with cool water no warmer than 98.6°F (37.0°C) approximately 1 hour before a meal. All doses should be completed at least 1 week before potential exposure.,Typhoid,07/22/2018,All Valid: Forecast Test,08/19/2016,01/16/2019,Recommended based on Condition,Added description,4
2016-UC-0149,Microbiology laboratorian who works frequently with S. typhi carrier and has not received the Typhoid vaccine.,10/15/1980,M,51,Microbiology laboratorians who work frequently with S. typhi,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,10/15/1982,10/15/1982,,This vaccine should be given at least 2 weeks before potential exposure.  Primary vaccination with live-attenuated Ty21a vaccine consists of one enteric-coated capsule taken on alternate days (day 0 2 4 and 6) for a total of four capsules. The capsules must be kept refrigerated (not frozen). Each capsule should be taken with cool water no warmer than 98.6°F (37.0°C) approximately 1 hour before a meal. All doses should be completed at least 1 week before potential exposure.,Typhoid,08/16/2016,No Doses Administered,08/29/2016,05/02/2019,Recommended based on Condition,Updated test case to forecast dose number 1 at age 6 years of age added description.,4
2016-UC-0150,Patient is a microbiology laboratorian who works frequently with S. typhi carrier and has received the Typhoid vaccine.,10/15/1980,M,51,Microbiology laboratorians who work frequently with S. typhi,,,,,,,,Not Complete,08/16/2016,Typhoid oral live attenuated,25,PMC,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,08/16/2021,08/16/2021,,This vaccine should be given at least 2 weeks before potential exposure.  Primary vaccination with live-attenuated Ty21a vaccine consists of one enteric-coated capsule taken on alternate days (day 0 2 4 and 6) for a total of four capsules. The capsules must be kept refrigerated (not frozen). Each capsule should be taken with cool water no warmer than 98.6°F (37.0°C) approximately 1 hour before a meal. All doses should be completed at least 1 week before potential exposure.,Typhoid,08/16/2016,All Valid: Forecast Test,08/29/2016,01/16/2019,Recommended based on Condition,Updated the CVX code to 25 added description,4
2016-UC-0151,Patient is 52 years of age and travelling to a country at risk for Yellow Fever transmission.,07/01/1964,F,162,Travel to areas at risk for Yellow Fever transmission,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,04/01/1965,04/01/1965,,A single primary dose of yellow fever vaccine provides long-lasting protection and is adequate for most travelers but additional doses of yellow fever vaccine are recommended for certain travelers with ongoing risk.  Women who were pregnant (regardless of trimester) when they received their initial dose of yellow fever vaccine should receive 1 additional dose of yellow fever vaccine  Persons who received a hematopoietic stem cell transplant after receiving a dose of yellow fever vaccine and who are sufficiently immunocompetent to be safely vaccinated should be revaccinated.  A booster dose may be given to travelers who received their last dose of yellow fever vaccine at least 10 years previously and who will be in a higher-risk setting based on season location activities and duration of their travel.  Persons who were infected with HIV when they received their last dose of yellow fever vaccine should receive a dose every 10 years if they continue to be at risk for yellow fever virus infection.,Yellow Fever,09/01/2016,No Doses Administered,08/22/2016,01/16/2019,Recommended based on Condition,added description,4
2016-UC-0152,Patient is travelling to a country at risk for Yellow Fever transmission and has received the Yellow Fever risk 1 dose series.,07/01/1964,F,162,Travel to areas at risk for Yellow Fever transmission,,,,,,,,Complete,09/01/2016,Yellow Fever,37,PMC,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,A single primary dose of yellow fever vaccine provides long-lasting protection and is adequate for most travelers but additional doses of yellow fever vaccine are recommended for certain travelers with ongoing risk.  Women who were pregnant (regardless of trimester) when they received their initial dose of yellow fever vaccine should receive 1 additional dose of yellow fever vaccine  Persons who received a hematopoietic stem cell transplant after receiving a dose of yellow fever vaccine and who are sufficiently immunocompetent to be safely vaccinated should be revaccinated.  A booster dose may be given to travelers who received their last dose of yellow fever vaccine at least 10 years previously and who will be in a higher-risk setting based on season location activities and duration of their travel.  Persons who were infected with HIV when they received their last dose of yellow fever vaccine should receive a dose every 10 years if they continue to be at risk for yellow fever virus infection.,Yellow Fever,09/01/2016,All Valid: Forecast Test,08/22/2016,01/16/2019,Recommended based on Condition,Added description,4
2016-UC-0153,Child is 3 years old with cochlear implants and has an incomplete schedule (only received 1 dose at 4 months) of the PCV 13 series.,01/08/2013,M,11,Cochlear implants,,,,,,,,Not Complete,05/08/2013,PCV 13,133,PFR,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,07/03/2013,07/03/2013,,When cochlear implant placement is being planned PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.,Pneumococcal,02/12/2016,All Valid: Forecast Test,08/30/2016,01/17/2019,Recommended based on Condition,Updated to reflect the correct forecasting date added description.,4
2016-UC-0154,Patient is 3 years old with cochlear implants has received one standard dose of the PCV 13 series and has received the first dose of the risk 2-5 years 3 dose series.,01/08/2013,M,11,Cochlear implants,,,,,,,,Not Complete,05/08/2013,PCV 13,133,PFR,Valid,standard,,02/12/2016,PCV 13,133,PFR,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,04/08/2016,04/08/2016,,When cochlear implant placement is being planned PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.,Pneumococcal,02/12/2016,All Valid: Forecast Test,08/30/2016,01/17/2019,Recommended based on Condition,Added description,4
2016-UC-0155,Patient is 3 years old with cochlear implants and has received one standard dose of the PCV 13 series and has received the second dose of the risk 2-5 years 3 dose series.,01/08/2013,M,11,Cochlear implants,,,,,,,,Not Complete,05/08/2013,PCV 13,133,PFR,Valid,standard,,02/12/2016,PCV 13,133,PFR,Valid,risk,,04/08/2016,PCV 13,133,,Valid,Risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4,06/03/2016,06/03/2016,,When cochlear implant placement is being planned PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.,Pneumococcal,04/08/2016,All Valid: Forecast Test,08/30/2016,01/17/2019,Recommended based on Condition,Added description,4
2016-UC-0156,Patient is 4 years old with cochlear implants has received three doses of the PCV13 vaccine and one dose of the PPSV23 vaccine.,05/17/2012,M,11,Cochlear implants,,,,,,,,Not Complete,09/27/2012,PCV 13,133,PFR,Valid,standard,,12/13/2012,PCV 13,133,PFR,Valid,risk,,05/17/2013,PCV 13,133,PFR or WAL,Valid,risk,,05/21/2016,PPSV23,33,PFR or WAL,Valid,Risk,,,,,,,,,,,,,,,,,,,,,,,5,05/17/2077,05/17/2077,,When cochlear implant placement is being planned PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.,Pneumococcal,05/21/2016,All Valid: Forecast Test,08/31/2016,01/17/2019,Recommended based on Condition,Added description,4
2016-UC-0157,Patient is 19 years of age and smokes cigarettes and has not received the PPSV23 vaccine.,03/08/1997,F,42,Smoke cigarettes,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,03/08/2003,03/08/2003,03/07/2062,,Pneumococcal,04/16/2016,No Doses Administered,08/30/2016,01/17/2019,Recommended based on Condition,Updated to add Past Due date added description,4
2016-UC-0158,Patient is 19 years of age smokes cigarettes and has received the Pneumococcal risk 1 dose vaccine.,03/08/1997,F,42,Smoke cigarettes,,,,,,,,Not Complete,04/16/2016,PPSV23,33,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,03/08/2062,03/08/2062,,,Pneumococcal,04/16/2016,All Valid: Forecast Test,08/30/2016,01/17/2019,Recommended based on Condition,added description,4
2016-UC-0159,Child is 8 years of age with cerebrospinal fluid leaks and has not received (vaccine naive)PCV13 nor PPSV23 vaccine.,09/14/2008,M,10,Cerebrospinal fluid leaks,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,09/14/2014,09/14/2014,,,Pneumococcal,09/14/2016,No Doses Administered,09/01/2016,01/17/2019,Recommended based on Condition,added description,4
2016-UC-0160,Patient is 8 years of age and has cerebrospinal fluid leaks and has received the PCV13 vaccine but not the PPSV23 vaccine.,09/14/2008,M,10,Cerebrospinal fluid leaks,,,,,,,,Not Complete,09/14/2016,PCV 13,133,PFR,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,11/09/2016,11/09/2016,,,Pneumococcal,09/14/2016,All Valid: Forecast Test,09/01/2016,01/17/2019,Recommended based on Condition,Added description,4
2016-UC-0161,Patient is 8 years of age has cerebrospinal fluid leaks and has received a dose of the PCV 13 and a dose of the PPSV23 vaccine.,09/14/2008,M,10,Cerebrospinal fluid leaks,,,,,,,,Not Complete,09/14/2016,PCV 13,133,PFR,Valid,risk,,11/09/2016,PPSV 23,33,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,09/14/2073,09/14/2073,,,Pneumococcal,11/09/2016,All Valid: Forecast Test,09/01/2016,01/17/2019,Recommended based on Condition,Added description,4
2016-UC-0162,Patient is 15 years of age and has cerebrospinal fluid leaks and has received a dose of the PPSV23 vaccine but not the PCV13 vaccine.,03/16/2001,F,10,Cerebrospinal fluid leaks,,,,,,,,Not Complete,05/02/2016,PPSV 23,33,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,06/27/2016,06/27/2016,,,Pneumococcal,05/02/2016,All Valid: Forecast Test,09/01/2016,01/17/2019,Recommended based on Condition,Added description,4
2016-UC-0163,Patient is 15 years of age and has cerebrospinal fluid leaks and has received the second dose of the Pneumococcal risk 2-dose PPSV-PCV series vaccine.,03/16/2001,F,10,Cerebrospinal fluid leaks,,,,,,,,Not Complete,05/02/2016,PPSV 23,33,MSD,Valid,risk,,06/27/2016,PCV 13,133,PFR,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,03/16/2066,03/16/2066,,,Pneumococcal,06/27/2016,All Valid: Forecast Test,09/01/2016,01/17/2019,Recommended based on Condition,added description,4
2016-UC-0164,Patient is 39 years of age has cochlear implants and has received the PPSV23 vaccine but not PCV13.,05/01/1977,M,11,Cochlear implants,,,,,,,,Not Complete,08/01/2016,PPSV 23,33,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,08/01/2017,08/01/2017,,When cochlear implant placement is being planned PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.,Pneumococcal,08/01/2016,All Valid: Forecast Test,09/02/2016,01/14/2019,Recommended based on Condition,Update to reflect the correct forecasting date added description.,4
2016-UC-0165,Patient is 39 years of age has cochlear implants has received the PCV13 vaccine one year after the PPSV23 vaccine dose.,05/01/1977,M,11,Cochlear implants,,,,,,,,Not Complete,08/01/2016,PPSV 23,33,MSD,Valid,risk,,08/01/2017,PCV 13,133,PFR,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,05/01/2042,05/01/2042,,When cochlear implant placement is being planned PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.,Pneumococcal,08/01/2017,All Valid: Forecast Test,09/02/2016,01/17/2019,Recommended based on Condition,Updated forecast vaccine type added description,4
2016-UC-0166,Patient is a two year old child with sickle cell disease who has completed the PCV 13 vaccine standard series but has not received a dose of the PPSV 23 vaccine.,03/21/2010,F,160,Anatomical or functional asplenia,,,,,,,,Not Complete,05/21/2010,PCV 13,133,PFR,Valid,standard,,07/21/2010,PCV 13,133,PFR,Valid,standard,,09/21/2010,PCV 13,133,PFR,Valid,standard,,05/21/2012,PCV 13,133,PFR,Valid,standard,,,,,,,,,,,,,,,,,,,,,,,5,07/16/2012,07/16/2012,,When elective splenectomy is being planned PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.,Pneumococcal,05/21/2012,All Valid: Forecast Test,09/02/2016,05/08/2019,Recommended based on Condition,Updated age of patient in 4 dose. Added description,4
2016-UC-0167,Patient is 6 years of age has sickle cell disease has completed the PCV 13 standard vaccine series and has received a dose of PPSV23 series.,03/21/2010,F,160,Anatomical or functional asplenia,,,,,,,,Not Complete,05/21/2010,PCV 13,133,PFR,Valid,standard,,07/21/2010,PCV 13,133,PFR,Valid,standard,,09/21/2010,PCV 13,133,PFR,Valid,standard,,05/21/2012,PCV 13,133,PFR,Valid,standard,,05/28/2016,PPSV 23,33,MSD,Valid,Risk,,,,,,,,,,,,,,,,6,05/28/2021,05/28/2021,,When elective splenectomy is being planned PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.,Pneumococcal,05/28/2016,All Valid: Forecast Test,09/02/2016,01/17/2019,Recommended based on Condition,Added description,4
2016-UC-0168,Patient is now 11 years of age has sickle cell disease has completed the PCV 13 standard vaccine series received the first and 5 year booster dose of PPSV23 series.,03/21/2010,F,160,Anatomical or functional asplenia,,,,,,,,Not Complete,05/21/2010,PCV 13,133,PFR,Valid,standard,,07/21/2010,PCV 13,133,PFR,Valid,standard,,09/21/2010,PCV 13,133,PFR,Valid,standard,,05/21/2011,PCV 13,133,PFR,Valid,standard,,05/28/2016,PPSV 23,33,MSD,Valid,Risk,,05/28/2021,PPSV 23,33,,Valid,Risk,,,,,,,,,7,03/21/2075,03/21/2075,,When elective splenectomy is being planned PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.,Pneumococcal,05/28/2021,All Valid: Forecast Test,09/02/2016,01/17/2019,Recommended based on Condition,Add description,4
2016-UC-0169,Patient is 9 years of age has HIV infection and has only received a dose of PPSV23 vaccine but has not received a dose of the PCV 13 vaccine.,04/13/2007,M,155,HIV/AIDS - not severely immunocompromised,,,,,,,,Not Complete,06/01/2016,PPSV 23,33,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,07/27/2016,07/27/2016,,,Pneumococcal,06/01/2016,All Valid: Forecast Test,09/02/2016,01/29/2019,Recommended based on Condition,Added description,4
2016-UC-0170,Patient is 9 years of age has HIV infection and has received a dose of PPSV23 vaccine and a dose of the PCV 13 vaccine 8 weeks later.,04/13/2007,M,155,HIV/AIDS - not severely immunocompromised,,,,,,,,Not Complete,06/01/2016,PPSV 23,33,MSD,Valid,risk,,07/27/2016,PCV 13,133,PFR,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,06/01/2021,06/01/2021,,,Pneumococcal,07/27/2016,All Valid: Forecast Test,09/02/2016,01/29/2019,Recommended based on Condition,Added description,4
2016-UC-0171,Patient is now 14 years of age has HIV infection and has received two doses ( one is booster dose 5 years later) of PPSV23 and a dose of PCV13.,04/13/2007,M,155,HIV/AIDS - not severely immunocompromised,,,,,,,,Not Complete,06/01/2016,PPSV 23,33,MSD,Valid,risk,,07/27/2016,PCV 13,133,PFR,Valid,risk,,06/01/2021,PPSV 23,33,MSD,Valid,Risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4,04/13/2072,04/13/2072,,,Pneumococcal,06/01/2021,All Valid: Forecast Test,09/02/2016,01/29/2019,Recommended based on Condition,Added description,4
2016-UC-0172,Patient is 22 years of age and has General malignant neoplasm and has received a dose of PPSV23 but not PCV13.,06/13/1994,M,156,Generalized malignant neoplasm,,,,,,,,Not Complete,08/21/2016,PPSV 23,33,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,08/21/2017,08/21/2017,,,Pneumococcal,08/21/2016,All Valid: Forecast Test,09/02/2016,01/29/2019,Recommended based on Condition,Updated earliest and recommended forecast dates to 1 years per ACIP guidelines added description,4
2016-UC-0173,Patient is 22 years of age with General malignant neoplasm and has received a dose of PPSV23 and a dose PCV13 at a year later.,06/13/1994,M,156,Generalized malignant neoplasm,,,,,,,,Not Complete,08/21/2016,PPSV 23,33,MSD,Valid,risk,,08/21/2017,PCV 13,133,PFR,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,08/21/2021,08/21/2021,,,Pneumococcal,08/21/2017,All Valid: Forecast Test,09/02/2016,12/02/2019,Recommended based on Condition,Updated earliest and recommended forecast date to 5 years after most previous dose of PPSV23 added description,4.1
2016-UC-0174,Patient is 27 years of age and has General malignant neoplasm has received a 2 doses of PPSV23 and a dose of PCV13.,06/13/1994,M,156,Generalized malignant neoplasm,,,,,,,,Not Complete,08/21/2016,PPSV 23,33,MSD,Valid,risk,,08/21/2017,PCV 13,133,PFR,Valid,risk,,08/21/2022,PPSV 23,33,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4,06/13/2059,06/13/2059,06/13/2059,,Pneumococcal,08/21/2022,All Valid: Forecast Test,09/02/2016,01/29/2019,Recommended based on Condition,Added description,4
2016-UC-0175,Patient is 14 years of age and has Persistent Component properdin or Factor B deficiency has previously received 2 doses of the PPSV23 vaccine but has not received a dose of PCV13.,04/04/2002,F,151,Persistent complement properdin or factor B deficiency,,,,,,,,Not Complete,04/16/2011,PPSV 23,33,MSD,Valid,risk,,04/16/2016,PPSV 23,33,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,06/11/2016,06/11/2016,,,Pneumococcal,04/16/2016,All Valid: Forecast Test,09/06/2016,01/29/2019,Recommended based on Condition,Added description,4
2016-UC-0176,Patient is 14 years of age and has Persistent Component properdin or Factor B deficiency has previously received 2 doses of the PPSV23 vaccine and has received a dose of PCV13 vaccine 8 weeks later.,04/04/2002,F,151,Persistent complement properdin or factor B deficiency,,,,,,,,Not Complete,04/16/2011,PPSV 23,33,MSD,Valid,risk,,04/16/2016,PPSV 23,33,MSD,Valid,risk,,06/11/2016,PCV 13,133,PFR,Valid,Risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4,04/04/2067,04/04/2067,,,Pneumococcal,06/11/2016,All Valid: Forecast Test,09/06/2016,12/02/2019,Recommended based on Condition,Removed the past due date Added description,4.1
2016-UC-0177,Patient is 25 years of age with nephrotic syndrome has previously received two doses of PPSV23 vaccine but has not received a dose of the PCV13 vaccine.,07/02/1986,M,167,Nephrotic Syndrome,,,,,,,,Not Complete,08/03/2006,PPSV 23,33,MSD,Valid,risk,,08/03/2011,PPSV 23,33,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,08/03/2012,08/03/2012,,,Pneumococcal,08/03/2011,All Valid: Forecast Test,09/06/2016,01/29/2019,Recommended based on Condition,Added description and Updated past due date,4
2016-UC-0178,Patient has nephrotic syndrome has received two doses of the PPSV vaccine and a dose of the PCV13 vaccine,07/02/1986,M,167,Nephrotic Syndrome,,,,,,,,Not Complete,08/03/2006,PPSV 23,33,MSD,Valid,risk,,08/03/2011,PPSV 23,33,MSD,Valid,risk,,08/03/2012,PCV 13,133,PFR,Valid,Risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4,07/02/2051,07/02/2051,07/02/2051,,Pneumococcal,08/03/2012,All Valid: Forecast Test,09/06/2016,01/29/2019,Recommended based on Condition,Added Past Due date added description,4
2016-UC-0179,Patient is a traveler who plans to spend a month or longer in an endemic area and has experienced a severe allergic reaction after previous dose of Japanese Encephalitis vaccine.,12/10/1977,M,82,Severe allergic reaction after previous dose of Japanese Encephalitis,,165,Longer-term (e.g. 1 month or more) travel to a JE-endemic area,,,,,Contraindicated,05/15/2016,Japanese Encephalitis VC,134,VAL,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Japanese Encephalitis,05/15/2016,All Valid: Forecast Test,08/23/2016,01/29/2019,Not recommended: contraindication,Updated to reflect an additional contraindication/observation.,4
2016-UC-0180,Patient is a traveler who plans to spend a month in an endemic area and has had an adverse reaction to a vaccine component of Japanese Encephalitis vaccine.,08/19/1981,F,80,Adverse reaction to vaccine component,,165,Longer-term (e.g. 1 month or more) travel to a JE-endemic area,,,,,Contraindicated,11/01/2015,Japanese Encephalitis VC,134,VAL,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Japanese Encephalitis,11/01/2015,All Valid: Forecast Test,08/23/2016,01/29/2019,Not recommended: contraindication,Added description,4
2016-UC-0181,Patient is an animal handler with no previous history of the Rabies vaccination.,09/24/1976,M,61,Animal handlers,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,09/24/1976,09/24/1976,,,Rabies,08/01/2016,No Doses Administered,08/25/2016,02/25/2019,Recommended based on Condition,Added description,4
2016-UC-0182,Patient is an animal handler and has received the first dose of the Rabies risk 3 dose frequent vaccine series.,09/24/1976,M,61,Animal handlers,,,,,,,,Not Complete,08/01/2016,Rabies - IM Diploid cell culture,175,NOV,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,08/08/2016,08/08/2016,,,Rabies,08/01/2016,All Valid: Forecast Test,08/25/2016,02/25/2019,Recommended based on Condition,Updated CVX code from 18 to 175/176 added description,4
2016-UC-0183,Patient is an animal handler and has received the second dose of the Rabies risk 3 dose frequent vaccine series.,09/24/1976,M,61,Animal handlers,,,,,,,,Not Complete,08/01/2016,Rabies - IM Diploid cell culture,175,NOV,Valid,risk,,08/08/2016,Rabies - IM Diploid cell culture,175,NOV,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,08/22/2016,08/22/2016,08/28/2016,,Rabies,08/08/2016,All Valid: Forecast Test,08/25/2016,02/25/2019,Recommended based on Condition,Updated Past Due date added description,4
2016-UC-0184,Patient is an animal handler and has received three doses of the Rabies risk 3 dose frequent vaccine series.,09/24/1976,M,61,Animal handlers,,,,,,,,Not Complete,08/01/2016,Rabies - IM Diploid cell culture,175,NOV,Valid,risk,,08/08/2016,Rabies - IM Diploid cell culture,175,NOV,Valid,risk,,08/22/2016,Rabies - IM Diploid cell culture,175,NOV,Valid,Risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4,08/22/2018,08/22/2018,,The 2 year booster should only be given after a serum sample has been tested for rabies virus neutralizing antibody. The booster should be administered if the serum titer fails to maintain a value of at least complete neutralization of a 1:5 serum dilution by rapid fluorescent focus inhibition test.,Rabies,08/22/2016,All Valid: Forecast Test,08/25/2016,02/25/2019,Recommended based on Condition,Updated Earliest and Recommended Date to reflect 2 years after the last dose date.,4
2016-UC-0185,Patient is a veterinarian staffer and has experienced a severe allergic reaction after previous dose of Rabies vaccine.,05/13/1984,F,113,Severe allergic reaction after previous dose of Rabies,,60,Veterinarians and their staff,,,,,Contraindicated,07/29/2016,Rabies - IM Diploid cell culture,175,NOV,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Rabies,07/29/2016,All Valid: Forecast Test,08/26/2016,02/25/2019,Not recommended: contraindication,Updated to reflect an additional contraindication or observation added a description.,4
2016-UC-0186,Patient has adverse reaction to Rabies vaccine component,03/17/1986,F,80,Adverse reaction to vaccine component,,60,Veterinarians and their staff,,,,,Contraindicated,01/13/2016,Rabies - IM Diploid cell culture,175,NOV,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Rabies,01/13/2016,All Valid: Forecast Test,08/26/2016,02/25/2019,Not recommended: contraindication,Updated to reflect an additional contraindication or observation added a description.,4
2016-UC-0187,Patient has experienced a severe allergic reaction to egg protein.,12/15/1968,M,101,Allergic reaction to egg protein,,45,Travel to country with a Yellow Fever vaccination entry requirement,,,,,Contraindicated,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Yellow Fever,03/13/2016,All Valid: Forecast Test,08/22/2016,02/25/2019,Recommended based on Condition,Added descriptions,4
2016-UC-0188,Patient is a microbiology laboratorian who works frequently with S.Typhi Carrier and has received the Risk 4 dose vaccine series and the 5 year booster dose.,03/10/1977,F,51,Microbiology laboratorians who work frequently with S. typhi,,,,,,,,Not Complete,07/10/2016,Typhoid capsular polysaccharide,25,PMC,Valid,risk,,07/10/2021,Typhoid capsular polysaccharide,25,PMC,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,07/10/2026,07/10/2026,,This vaccine should be given at least 2 weeks before potential exposure.  Primary vaccination with live-attenuated Ty21a vaccine consists of one enteric-coated capsule taken on alternate days (day 0 2 4 and 6) for a total of four capsules. The capsules must be kept refrigerated (not frozen). Each capsule should be taken with cool water no warmer than 98.6°F (37.0°C) approximately 1 hour before a meal. All doses should be completed at least 1 week before potential exposure.,Typhoid,07/10/2021,All Valid: Forecast Test,08/29/2016,03/04/2019,Recommended based on Condition,Updated to reflect an additional Condition/observation and updated booster dose to be administered at 5 years later.,4
2016-UC-0189,Patient is a microbiology laboratorian who has experience a severe allergic reaction after previous dose of Typhoid vaccine,10/08/1972,M,84,Severe allergic reaction after previous dose of Typhoid,,51,Microbiology laboratorians who work frequently with S. typhi,,,,,Contraindicated,08/15/2016,Typhoid capsular polysaccharide,101,PMC,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Typhoid,08/15/2016,All Valid: Forecast Test,08/22/2016,03/04/2019,Recommended based on Condition,Updated to reflect an additional contraindication/observation.,4
2016-UC-0190,Patient is 22 years of age smokes and has asthma and has not received the Pneumococcal risk dose.,07/22/1994,M,27,Asthma,,42,Smoke cigarettes,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,07/22/2000,07/22/2000,07/21/2059,,Pneumococcal,10/13/2016,No Doses Administered,08/22/2016,03/04/2019,Recommended based on Condition,Updated to reflect an additional Condition/observation. Also updated Past Due date.,4
2016-UC-0191,Patient is a smoker has asthma and has received the Pneumococcal risk 1 dose series.,07/22/1994,M,27,Asthma,,42,Smoke cigarettes,,,,,Not Complete,10/13/2016,PPSV 23,33,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,07/22/2059,07/22/2059,,,Pneumococcal,10/13/2016,All Valid: Forecast Test,08/22/2016,03/04/2019,Recommended based on Condition,Updated to reflect an additional Condition/observation.,4
2016-UC-0192,Patient is a smoker has diabetes and asthma and has not received the Pneumococcal risk 1 dose vaccine.,08/14/1965,M,14,Diabetes,,27,Asthma,,42,Smoke cigarettes,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,08/14/1971,08/14/1971,08/13/2030,,Pneumococcal,07/12/2016,No Doses Administered,08/26/2016,03/04/2019,Recommended based on Condition,Updated to reflect correct Past Due date,4
2016-UC-0193,Patient is a smoker has diabetes and has asthma and has received the Pneumococcal risk 1 dose series.,08/14/1965,M,14,Diabetes,,27,Asthma,,42,Smoke cigarettes,,Not Complete,07/12/2016,PPSV 23,33,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,08/14/2030,08/14/2030,,,Pneumococcal,07/12/2016,All Valid: Forecast Test,08/26/2016,03/04/2019,Recommended based on Condition,Updated to reflect an additional Condition/observation.,4
2016-UC-0194,Patient is 28 years of age is MSM has HIV is an illicit drug user and has not been vaccinated with the Hep B vaccine.,03/23/1988,M,36,Men who have sex with men,,155,HIV/AIDS - not severely immunocompromised,,41,Illicit injection drug use,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,03/23/2007,03/23/2007,,,HepB,05/19/2016,No Doses Administered,08/30/2016,03/04/2019,Recommended based on Condition,Added description,4
2016-UC-0195,Patient is MSM has HIV and is an illicit drug user and has received the first dose of the Hep B vaccine (Hep B Risk 3-dose series),03/23/1988,M,36,Men who have sex with men,,155,HIV/AIDS - not severely immunocompromised,,41,Illicit injection drug use,,Not Complete,05/19/2016,Hep B Adult,43,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,06/16/2016,06/16/2016,,,HepB,05/19/2016,All Valid: Forecast Test,08/30/2016,03/04/2019,Recommended based on Condition,Added description,4
2016-UC-0196,Patient is MSM has HIV is an illicit drug user and has received the second dose of the Hep B Risk 3-dose series,03/23/1988,M,36,Men who have sex with men,,155,HIV/AIDS - not severely immunocompromised,,41,Illicit injection drug use,,Not Complete,05/19/2016,Hep B Adult,43,MSD,Valid,risk,,06/16/2016,Hep B Adult,43,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,09/19/2016,09/19/2016,,,HepB,06/16/2016,All Valid: Forecast Test,08/30/2016,03/04/2019,Recommended based on Condition,Updated Earliest and Recommended to represent a 4 month interval after the 1st dose.,4
2016-UC-0197,Patient is MSM has HIV is an illicit drug user and has received all three doses of the Hep B Risk 3-dose series,03/23/1988,M,36,Men who have sex with men,,155,HIV/AIDS - not severely immunocompromised,,41,Illicit injection drug use,,Complete,05/19/2016,Hep B Adult,43,MSD,Valid,risk,,06/16/2016,Hep B Adult,43,MSD,Valid,risk,,09/19/2016,Hep B Adult,43,MSD,Valid,Risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,HepB,09/19/2016,All Valid: Forecast Test,08/30/2016,03/14/2019,Recommended based on Condition,Updated the third dose to reflect 4 mos from dose #1 added general description,4
2016-UC-0198,Patient is 39 years of age a microbiologist who is frequently exposed to Neisseria meningitidis and who plans to travel to countries where meningococcal disease is endemic.,07/13/1977,F,50,Microbiologists routinely exposed to Neisseria meningitidis,,164,Travel to or are residents of countries in which meningococcal disease is hyperendemic or epidemic,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,07/13/1979,07/13/1979,,,Meningococcal,08/02/2016,No Doses Administered,08/02/2016,03/14/2019,Recommended based on Condition,Updated to reflect an Earliest and Recommended data of 07/13/79.07/13/1979 added description.,4
2016-UC-0200,Patient is using dialysis and has had a previous severe allergic reaction to vaccine ingredient yeast (Energix B),04/28/1949,M,97,Severe allergic reaction after previous dose of Hepatitis B,,32,Dialysis patient,,,,,Contraindicated,05/17/2015,Hep B Adult,43,SKB,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,HepB,02/12/2016,All Valid: Forecast Test,08/26/2016,03/14/2019,Not recommended: contraindication,Updated to reflect an additional contraindication/observation.,4
2016-UC-0201,Patient is an animal handler who has had a severe allergic reaction after previous dose of Rabies,03/21/1979,M,113,Severe allergic reaction after previous dose of Rabies,,61,Animal handlers,,,,,Contraindicated,04/27/2016,Rabies - IM fibroblast culture,176,PMC,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Rabies,04/27/2016,All Valid: Forecast Test,08/26/2016,03/14/2019,Not recommended: contraindication,Updated to reflect an additional contraindication/observation.,4
2016-UC-0202,Patient is pregnant and does not have evidence of immunity from Rubella disease.,06/01/1985,F,7,Pregnant,,,,,,,,Contraindicated,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,Pregnant women who do not have evidence of immunity should receive MMR vaccine upon completion or termination of pregnancy and before discharge from the health care facility.,MMR,08/09/2016,No Doses Administered,08/09/2016,03/14/2019,Not recommended: contraindication,added description,4
2016-UC-0203,Patient is seeking protection and has had a severe allergic reaction after previous dose of Meningococcal B vaccine.,01/13/1995,M,116,Severe allergic reaction after previous dose of Meningococcal B,,1,Patient seeks protection,,,,,Contraindicated,06/28/2016,meningococcal B OMV,163,,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,MenB,06/28/2016,All Valid: Forecast Test,09/19/2016,03/14/2019,Not recommended: contraindication,Updated to reflect an additional contraindication/observation. Added description,4
2017-UC-0001,Patient is 9 years of age female with a history of sexual assault and has received two previous doses of HPV vaccine at least 6 months apart.,07/12/2006,F,169,History of sexual abuse or assault,,,,,,,,Complete,07/12/2015,9vHPV,165,MSD,Valid,risk,,01/23/2016,9vHPV,165,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,HPV,01/23/2016,All Valid: Forecast Test,01/09/2017,03/14/2019,Recommended based on Condition,Updated to reflect an additional Condition/observation.,4
2017-UC-0002,Patient is 15 years of age with a history of immunosuppressive therapy and has not received any previous doses of the HPV vaccine.,10/01/2001,M,158,Immunosuppressive therapy,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,10/01/2010,10/01/2012,10/28/2014,,HPV,01/03/2017,No Doses Administered,01/10/2017,12/02/2019,Recommended based on Condition,added a past due date.  Updated to reflect an additional Condition/observation.  Added description,4.1
2017-UC-0003,Patient is 15 years of age with a immunosuppressive therapy and has received the first dose of the HPV vaccine 3 dose series,10/01/2001,M,158,Immunosuppressive therapy,,,,,,,,Not Complete,01/08/2017,9vHPV,165,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,02/05/2017,02/05/2017,04/29/2017,,HPV,01/08/2017,All Valid: Forecast Test,02/02/2017,12/02/2019,Recommended based on Condition,Added past due date Added description,4.1
2017-UC-0004,Patient is 15 years of age with a immunosuppressive therapy and has received the first and second dose of the 3 dose HPV vaccine series.,10/01/2001,M,158,Immunosuppressive therapy,,,,,,,,Not Complete,01/08/2017,9vHPV,165,MSD,Valid,risk,,02/05/2017,9vHPV,165,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,06/08/2017,07/08/2017,09/04/2017,,HPV,07/08/2017,All Valid: Forecast Test,02/02/2017,03/18/2019,Recommended based on Condition,Added description,4
2017-UC-0005,Patient is 15 years of age with a history of immunosuppressive therapy and has received all three recommended doses of the HPV vaccine series.,10/01/2001,M,158,Immunosuppressive therapy,,,,,,,,Complete,01/08/2017,9vHPV,165,MSD,Valid,risk,,02/05/2017,9vHPV,165,MSD,Valid,risk,,06/08/2017,9vHPV,165,MSD,Valid,Risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,HPV,09/30/2017,All Valid: Forecast Test,02/02/2017,03/18/2019,Recommended based on Condition,Added description,4
2017-UC-0007,Patient is 11 years of age with generalized malignant neoplasm and has not received any previous does of the HPV vaccine.,06/02/2005,F,156,Generalized malignant neoplasm,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,06/02/2014,06/02/2016,06/29/2018,,HPV,08/01/2016,No Doses Administered,02/02/2017,12/02/2019,Recommended based on Condition,Added past due date Added description,4.1
2017-UC-0008,Patient is 11 years of age with generalized malignant neoplasm and has received the first dose of the HPV 3 dose vaccine series.,06/02/2005,F,156,Generalized malignant neoplasm,,,,,,,,Not Complete,08/01/2016,9vHPV,165,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,08/29/2016,08/29/2016,11/20/2016,,HPV,08/01/2016,All Valid: Forecast Test,02/02/2017,03/08/2019,Recommended based on Condition,Added description,4
2017-UC-0009,Patient is 11 years of age with generalized malignant neoplasm and has received the second dose of the HPV vaccine at 4 weeks later.,06/02/2005,F,156,Generalized malignant neoplasm,,,,,,,,Not Complete,08/01/2016,9vHPV,165,MSD,Valid,risk,,08/29/2016,9vHPV,165,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,01/01/2017,02/01/2017,03/28/2017,,HPV,08/29/2016,All Valid: Forecast Test,02/02/2017,12/02/2019,Recommended based on Condition,Updated earliest recommended and past due dates Added description,4.1
2017-UC-0010,Patient is 11 years of age with generalized malignant neoplasm and has received all three doses of the HPV 3 dose vaccine series.,06/02/2005,F,156,Generalized malignant neoplasm,,,,,,,,Complete,08/01/2016,9vHPV,165,MSD,Valid,risk,,08/29/2016,9vHPV,165,MSD,Valid,risk,,01/23/2017,9vHPV,165,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,HPV,01/23/2017,All Valid: Forecast Test,02/02/2017,03/26/2019,Recommended based on Condition,Added description,4
2017-UC-0011,Patient is an adult with persistent complement component deficiencies and has not received any previous doses of the Men B vaccine,09/02/1995,M,151,Persistent complement properdin or factor B deficiency,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,09/02/2005,09/02/2005,,,MenB,03/02/2017,No Doses Administered,03/20/2017,03/26/2019,Recommended based on Condition,Added description,4
2017-UC-0012,Patient is an adult with persistent complement component deficiencies and has received the first dose of the 2 dose Men B (Bexsero) vaccine,09/02/1995,M,151,Persistent complement properdin or factor B deficiency,,,,,,,,Not Complete,03/02/2017,meningococcal B OMV,163,NOV,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,03/30/2017,03/30/2017,,,MenB,03/02/2017,All Valid: Forecast Test,03/20/2017,12/02/2019,Recommended based on Condition,Updated recommended date from 03/30/3017 to 03/30/2017  Added description,4.1
2017-UC-0014,Patient is 38 years of age a microbiologist who is routinely exposed to Neisseria Meningitis and who has received the Risk 1 dose and the 5 years booster dose for Men ACWY,07/13/1977,F,50,Microbiologists routinely exposed to Neisseria meningitidis,,,,,,,,Not Complete,07/13/2010,Meningococcal MCV4P,114,PMC,Valid,risk,,07/13/2015,Meningococcal MCV4P,114,PMC,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,07/13/2020,07/13/2020,,,Meningococcal,07/13/2015,All Valid: Forecast Test,03/20/2017,03/26/2019,Recommended based on Condition,Added description,4
2017-UC-0015,Patient is 35 years of age and is traveling to a country that has active cholera transmission.,02/17/1982,M,8,Travel to an area of active cholera transmission,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,02/17/2000,02/17/2000,,,Cholera,07/18/2017,No Doses Administered,07/18/2017,03/26/2019,Recommended based on Condition,Added description,4
2017-UC-0016,Patient is 35 years of age and is traveling to a country that has active cholera transmission and has received the Cholera 1-dose series.,02/17/1982,M,8,Travel to an area of active cholera transmission,,,,,,,,Complete,07/18/2017,Cholera,174,PAX,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Cholera,07/18/2017,All Valid: Forecast Test,07/18/2017,03/26/2019,Recommended based on Condition,Added description,4
2017-UC-0017,Patient is 28 years of age and has a severe allergic reaction after previous dose of the Cholera vaccine.,08/01/1989,M,119,Severe allergic reaction after previous dose of cholera,,8,Travel to an area of active cholera transmission,,,,,Contraindicated,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Cholera,08/01/2017,No Doses Administered,08/22/2017,12/02/2019,Not recommended: contraindication,Added Observation Code 008 updated 080 to 119 Added description,4.1
2018-UC-0001,Patient is 15 years of age with persistent complement and has received the second dose of the Risk 3 dose Men B vaccine series at greater than or equal to 6 months after the first administered dose.,03/10/2003,M,151,Persistent complement properdin or factor B deficiency,,,,,,,,Complete,03/22/2018,meningococcal B recombinant,162,PFR,Valid,risk,,09/22/2018,meningococcal B recombinant,162,PFR,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,MenB,09/22/2018,All Valid: Forecast Test,10/19/2018,12/02/2019,Recommended based on Condition,Updated Vaccine Group type added description,4.1
2018-UC-0002,Patient is 7 years has persistent complement and has received the first dose of the MenACWY vaccine at 9 months second dose at 7 years.,01/02/2011,M,151,Persistent complement properdin or factor B deficiency,,,,,,,,Not Complete,10/02/2011,Meningococcal MCV4O,136,NOV,Valid,risk,,01/02/2018,Meningococcal MCV4O,136,NOV,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,01/02/2023,01/02/2023,,,Meningococcal,01/02/2018,All Valid: Forecast Test,10/29/2018,12/02/2019,Recommended based on Condition,Removed past due date added description,4.1
2018-UC-0004,Patient is 21 years of age with Hepatitis C Infection and has not received a dose of the Hep B vaccine.,06/23/1997,F,5,Hepatitis C virus infection,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,06/23/2016,06/23/2016,,,HepB,06/27/2018,No Doses Administered,12/17/2018,03/28/2019,Recommended based on Condition,added description,4
2018-UC-0005,Patient is 21 years of age with Hepatitis C Infection and has received the first dose in the Risk 2 (Heplisav) dose Hep B vaccine.,06/23/1997,F,5,Hepatitis C virus infection,,,,,,,,Not Complete,06/27/2018,HepB-CpG,189,DVX,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,07/25/2018,07/25/2018,08/21/2018,,HepB,06/27/2018,All Valid: Forecast Test,12/17/2018,03/28/2019,Recommended based on Condition,added description,4
2018-UC-0006,Patient is 21 years of age with Hepatitis C Infection and has received the second dose in the Risk 2 dose Hep B vaccine.,06/23/1997,F,5,Hepatitis C virus infection,,,,,,,,Complete,06/27/2018,HepB-CpG,189,DVX,Valid,risk,,07/25/2018,HepB-CpG,189,DVX,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,HepB,07/25/2018,All Valid: Forecast Test,12/17/2018,03/28/2019,Recommended based on Condition,added description,4
2019-UC-0001,Patient is 32 years of age and traveling to an endemic area during JE Transmission and has received the two primary doses and the booster dose.,09/10/1983,M,165,Longer-term (e.g. 1 month or more) travel to a JE-endemic area,,,,,,,,Complete,04/28/2016,Japanese Encephalitis VC,134,VAL,Valid,risk,,05/25/2016,Japanese Encephalitis VC,134,VAL,Valid,risk,,07/19/2019,Japanese Encephalitis VC,134,VAL,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Japanese Encephalitis,07/19/2019,All Valid: Forecast Test,03/01/2019,07/20/2019,Recommended based on Condition,Added booster dose information,4
2019-UC-0002,Patient is 2 years of age with chronic renal failure and no standard dose of PCV vaccine,04/29/2017,F,66,Chronic renal failure,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,04/29/2019,04/29/2019,,,Pneumococcal,07/01/2019,No Doses Administered,07/10/2019,07/10/2019,Recommended based on Condition,,4
2019-UC-0003,Patient is 2 years of age with chronic renal failure and has received the first dose of the PCV Vaccine.,04/29/2017,F,66,Chronic renal failure,,,,,,,,Not Complete,07/01/2019,PCV 13,133,,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,08/26/2019,08/26/2019,,,Pneumococcal,07/01/2019,All Valid: Forecast Test,07/10/2019,07/10/2019,Recommended based on Condition,,4
2019-UC-0008,Patient is 65 years with Cochlear implants and no doses of PCV 13 or PPSV23.,08/06/1954,M,11,Cochlear implants,,,,,,,,Not Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,08/06/2019,08/06/2019,08/06/2019,,Pneumococcal,08/06/2019,No Doses Administered,08/07/2019,12/02/2019,Recommended based on Condition,Updated test case observation code.,4.1
2019-UC-0009,Patient is 65 years with Cochlear implants with PCV13 dose but no PPSV.,08/06/1954,M,11,Cochlear implants,,,,,,,,Not Complete,08/06/2019,PCV 13,133,PFR,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,08/06/2020,08/06/2020,08/06/2020,,Pneumococcal,08/06/2019,All Valid: Forecast Test,08/07/2019,12/06/2019,Recommended based on Condition,Updated test case scenario.,4.1
2019-UC-0010,Patient is 65 years with Cochlear implants and has received PCV and PPSV dose,08/06/1954,M,11,Cochlear implants,,,,,,,,Complete,08/06/2019,PCV 13,133,PFR,Valid,risk,,08/06/2020,PPSV 23,33,PFR,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-,,,,,Pneumococcal,08/06/2020,All Valid: Forecast Test,08/07/2019,12/06/2019,Recommended based on Condition,Updated test case scenario.,4.1
2019-UC-0011,Patient is an adult with no history of the Hep B vaccine and is seek protection.,08/15/1971,F,1,Patient seeks protection,,,,,,,,Not Complete,,,,,,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,08/15/1990,08/15/1990,,,HepB,09/06/2019,No Doses Administered,12/06/2019,12/06/2019,Recommended based on Condition,,
2019-UC-0012,Patient is an adult with the first dose of the Hep B (Heplisav) vaccine.,08/15/1971,F,1,Patient seeks protection,,,,,,,,Not Complete,09/06/2019,HepB-CpG,189,DVX,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,10/04/2019,10/04/2019,11/01/2019,,HepB,09/06/2019,All Valid: Forecast Test,12/06/2019,12/06/2019,Recommended based on Condition,,
2019-UC-0013,Patient is an adult with two doses (Dose #1 is Heplisav vaccine) of the Hep B vaccine.,08/15/1971,F,1,Patient seeks protection,,,,,,,,Not Complete,09/06/2019,HepB-CpG,189,DVX,Valid,risk,,10/04/2019,Hep B,43,,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3,11/01/2019,11/01/2019,,,HepB,10/04/2019,All Valid: Forecast Test,12/06/2019,12/06/2019,Recommended based on Condition,,
2019-UC-0014,Patient is an adult with three doses of the Hep B vaccine.,08/15/1971,F,1,Patient seeks protection,,,,,,,,Not Complete,09/06/2019,Hep B,189,DVX,Valid,risk,,10/04/2019,Hep B,43,MSD,Valid,risk,,11/01/2019,Hep B,43,MSD,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4,11/29/2019,11/29/2019,,,HepB,11/01/2019,All Valid: Forecast Test,12/06/2019,12/06/2019,Recommended based on Condition,,
2019-UC-0015,Patient is an adult with four doses (first and fourth doses are Heplisav) of the Hep B vaccine,08/15/1971,F,1,Patient seeks protection,,,,,,,,Complete,09/06/2019,HepB-CpG,189,DVX,Valid,risk,,10/04/2019,Hep B,43,MSD,Valid,risk,,11/01/2019,Hep B,43,MSD,Valid,risk,,11/29/2019,HepB-CpG,189,DVX,Valid,risk,,,,,,,,,,,,,,,,,,,,,,,-,,,,,HepB,11/29/2019,All Valid: Forecast Test,12/06/2019,12/06/2019,Recommended based on Condition,,